CONFERENCE PROGRAM

University of Nebraska Medical Center
Nebraska Medicine

2024 PAN PACIFIC LYMPHOMA CONFERENCE

July 15-19 • Hyatt Regency Maui

Connect with us on X and using **#PPLC24 #IamUNMC**

DOWNLOAD THE EVENT APP

Make the most of your conference experience by downloading the FREE mobile app!

1. **Download and install the eventScribe app**
   - Scan the QR code or search for **eventScribe** in the Apple App Store or in Google Play.
   - Enter **PPLC 2024** in the Search for an Event field.

GET IT ON Google Play

Download on the App Store

2. **Login to the conference app**
   - To start using the conference app, select "**Create Account**" and type in **PPLC24** as the **event code**.
   - Enter **your name** and the **email address** that you used to register for this conference.

3. **Check your email for your access code**
   - Your access code is your password to login to the conference app.

Laptop and Desktop Users

1. **Visit the conference portal**
   - Go to **www.panpacificlymphoma.eventscribe.net**

2. **Login/Create an account**
   - If this is the first time you are accessing the portal, click **Sign Up** to create an account.
   - Enter **your name** and the **email address** that you used to register for this conference. Use **PPLC24** as the **event code**.

3. **Check your email for your access code**
   - Your access code is your password to login to the conference portal.

30 Years of Educational Excellence

Welcome to the 2024 Pan Pacific Lymphoma Conference!

Since its inception in 1994, PPLC has grown and become a premier international conference on the latest advances in lymphoma. This year's conference is a hybrid conference with a live in-person activity at the Hyatt Regency Maui Resort and Spa, Hawaii and a virtual option for attendees who are not able to travel. We are very happy to welcome over 670 attendees!

For your easy reference and convenience, we encourage you to download the conference mobile app or visit **www.panpacificlymphoma.eventscribe.net**. Please note that all reference to conference days and times follow Hawaii Standard Time (HST).

Here's what you can expect for the week:

- **Day 1 (Monday):** We will feature an Interprofessional Education Day, with various presentations for the interprofessional lymphoma team members with sessions covering The Day-to-Day Treating of Lymphoma Patients, How to Increase Your PI'ness and Practitioner Wellness.
- **Days 2-5 (Tuesday through Friday):** Expert faculty will present in scientific sessions covering Future Assessment of Lymphoma, Rock the Vote: Choosing Initial Therapy Wisely, Lymphoplasmacytic Lymphoma and Plasma Cell Dyscrasias, Just in "Case" You Asked Why I Did That, The Masked Lymphoma Doctor, Royal Lymphoma Rumble, Who Knows, Management of Orphan Diseases: When and How, and The Class of the Future is Here. Caron A. Jacobson, MD, MMSc will present the James O. Armitage Lymphoma Clinical Investigator Award Lecture and Elaine S. Jaffe, MD will deliver the Oliver Press Memorial Lecture, in memory of our esteemed colleague, Oliver W. Press, MD, PhD.
- **Days 2-4 (Tuesday through Thursday) afternoons:** Join us for the Ask the Experts sessions where we will discuss Indolent Non-Hodgkin Lymphoma (iNHL), DLBCL, cHL, PTCL and Waldenström Macroglobulinemia/Multiple Myeloma. Also, on Day 2/Tuesday, we will have our fast-paced Bierman's Brain Trivia – ERAS Edition with four teams competing for Day 3/Wednesday's Bierman's Brain Trivia Pineapple Cup Finals.
- **Days 1-5 (Monday through Friday):** If you are joining us in-person, please come visit the exhibits in the Grand Promenade.
- **Days 1-5 (Monday through Friday):** The conference e-poster gallery detailing the latest research in lymphoma and transplantation is available via the conference mobile app and online.
- **Day 2 (Tuesday) evening:** If you are attending in-person, please join us for the Welcome Reception from 7-9 p.m. in the Napili Gardens/Lawn where you can meet and network with other conference attendees. Light hors d'oeuvres and beverages will be served. Paid/registered guests are welcome to attend.
- **Day 4 (Thursday) evening:** In-person attendees are encouraged to join the Conference Dinner from 7-9 p.m. in Halona Kai. Dinner and beverages will be served. Paid/registered guests are welcome to attend.

Friendly reminders if you are attending in-person:

- Please be sure that you and your paid guests wear your conference badge at all times.
- The attire for this conference is casual; layered clothing is recommended as temperature in meeting rooms can fluctuate. A light jacket or sweater for outdoor evening activities is suggested. Leave your ties in your room!

If you are on X or Instagram, we encourage you to tag your photos and posts **#PPLC24** and **#IamUNMC**.

Once again, thank you for joining the 2024 Pan Pacific Lymphoma Conference. **Aloha!**

Conference Directors

James O. Armitage, MD
Joe Shapiro Professor of Medicine
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center

Matthew A. Lunning, DO, FACP
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
Assistant Vice Chancellor for Clinical Research
University of Nebraska Medical Center

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center

Conference Sponsors

University of Nebraska Medical Center (Accredited Provider)

As Nebraska's only public academic health sciences center, the University of Nebraska Medical Center (UNMC) is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving our state and its communities through award-winning outreach. UNMC is also committed to embracing the richness of diversity and is a major economic engine for the state of Nebraska. Led by Chancellor Jeffrey P. Gold, MD, UNMC has six colleges, two institutes, and a graduate studies program, serving nearly 4,300 students in more than two dozen programs. As an academic health science center, UNMC offers patients world-class health care, backed by the latest research innovations and practiced by faculty training the next generation of health care providers. With our hospital partner, Nebraska Medicine, UNMC provides services in about 50 specialties, including cancer, neurosciences, heart disease and others. Through this unique combination of academic, scientific, and health care experience, UNMC transforms the discoveries of the laboratory and theory of the classroom into breakthroughs for health.

The mission of the UNMC Continuing Education Programs is to provide specialized and inter-professional educational activities and support innovative research that facilitate individual skills and team-based performance that improves outcomes for patients and communities. Accordingly, UNMC's continuing education efforts aim to enhance the knowledge, skills, attitudes, competence and performance of health care professionals, ultimately improving patient outcomes and community health. This mission statement drives and unifies the continuing education efforts of all colleges and departments at UNMC.

The UNMC Center for Continuing Education (UNMC CCE) is one of this country's oldest accredited providers of continuing education to physicians, started in 1958. By 1967, UNMC CCE, was one of the first seven medical school programs to be ACCME accredited. Throughout its history, UNMC CCE's level and number of activities have grown in certified activities offered, variety of topics, delivery modes, and diversity of audience participants. UNMC CCE offers a broad range of activities from primary care issues to the latest developments in medicine and draws attendees throughout the region, nationally and internationally.

The UNMC College of Nursing Continuing interProfessional Development and Innovation (CiPDI) has been serving the profession since 1967. Through the creation of engaging continuing nursing education products using state-of-the-art technologies and innovative educational modalities, we strive to improve patient outcomes in Nebraska and around the globe. Our highly developed technical capabilities include instructional design and module development, video streaming, learning activity hosting, custom web development, visual design, dynamic web pages, and data collection, storage, and analysis. The UNMC CON CiPDI is approved by the California Board of Registered Nursing, and is able to take accredited programs into all 50 states and beyond.

In pursuit of our collective mission, UNMC CCE and UNMC CON CiPDI work collaboratively to sponsor multi-professional educational activities designed to improve the performance of the health care team and thus patient outcomes. To forward an integrated team-based approach and to facilitate multi-disciplinary and specialized training, UNMC achieved Joint Accreditation provider status effective through November 2024.

UNMC Department of Internal Medicine - Division of Oncology and Hematology

Renowned for the diagnosis, therapy, and research of lymphoma, the UNMC Department of Internal Medicine, Division of Oncology and Hematology has treated patients from all over the world. Patients come for consultation, initial diagnosis, second opinions, standard chemotherapy, participation in clinical research trials, stem cell transplants, and chimeric antigen receptor (CAR) T-cell therapies.

The Division of Oncology and Hematology is comprised of 35 faculty and physicians, with five specializing in lymphoma. The Division is interested in the diagnosis and treatment of all malignancies (cancers). Treatment may include chemotherapy, radiation therapy, immunotherapy, pathway targeted agents, or cellular therapies, including CAR T-cell therapy and stem cell transplantation.

The Division's physicians specialize in many types of cancers including lymphomas, leukemia, multiple myeloma, urologic, breast, lung, gastric and pancreatic, neuro-oncology, melanoma, hepatocellular, and other solid tumors.

Nebraska Medicine

Nebraska Medicine is the most esteemed academic health system in the region, consisting of 809 licensed beds at its two hospitals, more than 1,000 physicians, and 40 specialty and primary care clinics in Omaha and surrounding areas.

Nebraska Medicine and UNMC, its research and education partner, share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.

Nebraska Medicine traces its roots back to 1869 with the founding of Omaha's first hospital. In the decades since, it has built an international reputation for breakthroughs in cancer care, organ transplantation and treatment of infectious diseases.

For five straight years, Nebraska Medicine has also been named to Becker's Hospital Review's list of 100 Great Hospitals in America.

Fred & Pamela Buffett Cancer Center

The UNMC Fred & Pamela Buffett Cancer Center is the region's only National Cancer Institute (NCI) designated cancer center and is a member of the National Comprehensive Cancer Network (NCCN). The NCCN is an alliance of the nation's 33 leading cancer centers that develop and institute standards of care for the treatment of cancer and perform outcomes research with the goal of ensuring the delivery of high-quality, cost-effective services to cancer patients nationwide.

The Fred & Pamela Buffett Cancer Center opened in 2017 and continues to lead the world in the battle against cancer. By harnessing the most advanced biomedical and technological tools available, we are increasingly identifying the drivers behind cancer and creating precise therapies that improve outcomes. Through the use of genomics and other new diagnostic tools, we are employing precision medicine to customize therapies and care for each cancer patient.

While all forms of cancer will be treated at the Fred & Pamela Buffett Cancer Center, because of their prevalence in society and the center's potential to have a significant impact in their treatment, the following focus areas have been selected: breast cancer and other women's cancers, head and neck cancers, leukemia and lymphoma, lung cancer, pancreatic and gastrointestinal cancers, and prostate cancer.

The Fred & Pamela Buffet Cancer Center, along with the C.L. Werner Cancer Hospital, aim to provide the side-by-side, rapid development of therapeutics and delivery to patients with cancer.

Conference Information

Conference App

To make the most of your conference experience, we encourage you to use your mobile phone or tablet to access the conference app, or use your laptop or desktop to access the conference portal. See instructions on page 2.

Mobile Device Use

Please remember to turn your mobile device to silent or vibrate mode when attending educational sessions.

Internet Access

FREE

Complimentary WiFi is available in the conference area.
Network: UNMCPPLC24
Password: PPLC2024

Complimentary in-room WiFi is available for guests of the Hyatt Regency Maui Resort and Spa.

Photography and Audio Visual Recording Policy

Please be aware that during the 2024 Pan Pacific Lymphoma Conference, attendees, vendors, guests, and exhibitors may be photographed or videotaped by UNMC and/or third parties authorized by UNMC. Some of these photographs or videos may be displayed by UNMC in future publications or other materials. By virtue of your attendance, you agree to allow UNMC to use photographs of you in these promotional materials.

Photographs taken for the purpose of sharing on social media are allowed, but should avoid showing presentation slides. Please use **#PPLC24** and **#IamUNMC** when posting on social media.

Children and Other Accompanying Guests

PPLC 2024 does not offer childcare services. Due to limited seating capacity and the highly technical nature of the conference, children are not allowed to attend the educational sessions. For their safety, children must be accompanied by an adult at all times.

Registered accompanying guests may join conference registrants at the following food functions:

- Continental breakfasts (7–9 a.m.) and breaks as part of the main conference from Monday through Friday
- Welcome Reception on Tuesday evening
- Conference Dinner on Thursday evening

Name badges will be required.

Session and Room Assignments

1. **GRAND PROMENADE**
   Conference Registration
   Continental Breakfast
   Refreshment Break
   Exhibits
2. **MONARCHY BALLROOM 1-4**
   General Sessions
3. **MONARCHY BALLROOM 5-7**
   Bierman's Brain Trivia – ERAS Edition
   Ask the Experts
4. **NAPILI GARDENS/LAWN**
   Welcome Reception
5. **HALONA KAI AND POOL DECK**
   Conference Dinner

Registration Desk Hours

Sunday, July 14	2–4 p.m.
Monday, July 15	7 a.m. – 12:30 p.m.
Tuesday, July 16	7 a.m. – 12:30 p.m.
Wednesday, July 17	7 a.m. – 12:30 p.m.
Thursday, July 18	7 a.m. – 12:00 p.m.
Friday, July 19	7 a.m. – 12:00 p.m.

Exhibit Hours

Monday, July 15	7 a.m. – 12:15 p.m.
Tuesday, July 16	7 a.m. – 1 p.m. / 3–5 p.m.
Wednesday, July 17	7 a.m. – 1 p.m. / 3–5 p.m.
Thursday, July 18	7 a.m. – 1 p.m. / 3–5 p.m.
Friday, July 19	7–10 a.m.

Venue Floor Plan

Promenade Level

Lobby Level





Conference Agenda

All times are displayed in Hawaii Standard Time (HST)

Monday, July 15

INTERPROFESSIONAL EDUCATION DAY

7:00 a.m.	Conference Registration / Continental Breakfast	1
7:50 a.m.	Aloha / Conch Ceremony Matthew A. Lunning, DO, FACP	2
The Day-to-Day Treating of Lymphoma Patients MODERATOR: Ashley L. Schmitt, PA-C		2
8:00 a.m.	Updates on Utilization of Biosimilars and Generics in Lymphomas Jared E. Matya, PharmD, BCOP	
8:20 a.m.	Adjudicating Adverse Events in Lymphoma Patients Ashley L. Schmitt, PA-C	
8:40 a.m.	What the Social Worker Wished You Knew Angela Mortensen, LICSW	
9:00 a.m.	Optimal Team Utilization Round Table Christine Cox, RN Ann S. LaCasce, MD, MMSc Matthew A. Lunning, DO, FACP Caitlin A. Murphy, DNP, APRN, FNP-BC, AOCNP Ashley L. Schmitt, PA-C	
9:30 a.m.	Refreshment Break	1
How to Increase Your PI'ness MODERATOR: Katie Penas, MHA, CNMT, RT(N)		2
9:40 a.m.	How to Increase Your Odds in Obtaining an Investigator-Initiated Trial John P. Leonard, MD	
10:00 a.m.	How to Work with the Food and Drug Administration in Clinical Trials Grzegorz S. Nowakowski, MD	
10:20 a.m.	How to Recognize Clinical Trial Red Flags Katie Penas, MHA, CNMT, RT(N)	
10:40 a.m.	How to Increase Diversity in Clinical Trials Ruemu E. Birhiray, MD	
Practitioner Wellness MODERATOR: Tara M. Graff, DO, MS		2
11:00 a.m.	Taboo Topics in Healthcare David S. Kroll, MD	
11:20 a.m.	Achieving Career Balance: XX Perspective Sarah C. Rutherford, MD	
11:40 a.m.	Achieving Career Balance: XY Perspective Craig H. Moskowitz, MD	
12:00 p.m.	Adjourn	

Tuesday, July 16

7:00 a.m.	Conference Registration / Continental Breakfast	1
7:30 a.m.	Welcome James O. Armitage, MD and Julie M. Vose, MD, MBA	2
Future Assessment of Lymphoma MODERATOR: Kyle Skiermont, PharmD and Joann B. Sweasy, PhD		2
7:40 a.m.	What is the Governor in Lymphomagenesis Michael R. Green, PhD	
8:00 a.m.	Artificial Intelligence in Assessing Lymphoma Swaminathan P. Iyer, MD	
8:20 a.m.	Future of Liquid Biopsies in Lymphoma Davide Rossi, MD, PhD	
8:40 a.m.	Impact of World Health Organization or International Consensus Classification System in Lymphoma Elaine S. Jaffe, MD	
9:00 a.m.	Working Together to Improve Imaging Assessment in Lymphoma Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD Judith Trotman, MBChB, FRACP, FRCPA	
9:30 a.m.	Incorporating Liquid Biopsies into Clinical Practice in Aggressive Lymphomas Andrew D. Zelenetz, MD, PhD	
9:50 a.m.	Break	1

1 Grand Promenade | 2 Monarchy Ballroom 1-4 | 3 Monarchy Ballroom 5-7 | 4 Napili Gardens/Lawn | 5 Halona Kai and Pool Deck

Rock the Vote: Choosing Initial Therapy Wisely (2)

MODERATORS: Bruce D. Cheson, MD, FACP, FAAAS, FASCO and Matthew A. Lunning DO, FACP

10:05 a.m. Advanced Stage Classical Hodgkin Lymphoma
- ABVD-Based – Stephen M. Ansell, MD, PhD
- BV-Based – Ranjana H. Advani, MD
- Checkpoint Inhibitors Based – Alex F. Herrera, MD

10:35 a.m. Advanced Stage Large B-Cell Lymphoma
- R-CHOP – Jonathan W. Friedberg, MD, MMSc
- Pola-R-CHOP – Sonali M. Smith, MD
- Dose-Adjusted EPOCH-R – Mark Roschewski, MD

11:05 a.m. Advanced Stage Mantle Cell Lymphoma
- Bruton's Tyrosine Kinase Inhibitors + Chemo-Based – Michael Wang, MD
- Alternating Regimen – Martin H. Dreyling, MD, PhD
- BK/R-CHOP + Transplant – Kami J. Maddocks, MD

Lymphoplasmacytic Lymphoma and Plasma Cell Dyscrasias (2)

MODERATOR: Sarah L. Creamer, MD

11:35 a.m. When It's Not Just MGUS
Natalie S. Callander, MD

11:55 a.m. Induction Strategies in Lymphoplasmacytic Lymphoma (LPL)
R. Gregory Bociek, MD, MSc, FRCP(C)

12:15 p.m. B-Cell Maturation Antigen (BCMA) Directed Therapies in Multiple Myeloma
Krina K. Patel, MD, MSc

12:35 p.m. Non-BCMA Directed Cellular Therapies in Plasma Cell Dyscrasias
Yi Lin, MD, PhD

12:55 p.m. Adjourn

Bierman's Brain Trivia—ERAS Edition (3)

(ERAS ATTIRE REQUIRED)
MODERATOR: Matthew A. Lunning DO, FACP

3:00 p.m. Pineapple Cup Semifinals #1

Team 1: FEARLESS
- James O. Armitage, MD
- Bruce D. Cheson, MD, FACP, FAAAS, FASCO
- Elaine S. Jaffe, MD

Team 2: SPEAK NOW
- Steven M. Horwitz, MD
- Kerry J. Savage, MD, MSc, FRCPC
- Jason R. Westin, MD, MS, FACP

Pineapple Cup Semifinals #2

Team 1: FOLKLORE
- Ranjana H. Advani, MD
- Jonathan W. Friedberg, MD, MMSc
- Andrew D. Zelenetz, MD, PhD

Team 2: REPUTATION
- Alex F. Herrera, MD
- Caron A. Jacobson, MD, MMSc
- Sarah C. Rutherford, MD

Ask the Experts (3)

4:00 p.m. Indolent Non-Hodgkin Lymphoma (iNHL)
MODERATOR: R. Gregory Bociek, MD, MSc, FRCP(C)
Jonathan W. Friedberg, MD, MMSc
Caron A. Jacobson, MD, MMSc
Sarah C. Rutherford, MD

5:00 p.m. Adjourn

7:00 p.m. Welcome Reception (4)
Registered guests welcome.
Name badge required.

Wednesday, July 17

7:00 a.m. Continental Breakfast (1)

Just in "Case" You Asked Why I Did That (2)

MODERATOR: Philip J. Bierman, MD

7:00 a.m. Early Relapsing Follicular Lymphoma
- Auto Transplant – Craig S. Sauter, MD
- Bispecific Antibody – Gilles Salles, MD, PhD
- CAR-T – Sarah C. Rutherford, MD

7:45 a.m. Early Relapsing Large B-Cell Lymphoma
- Chemotherapy + Auto Transplant – R. Gregory Bociek, MD, MSc, FRCP(C)
- CAR-T – Jason R. Westin, MD, MS, FACP
- Neither – Nancy L. Bartlett, MD

8:30 a.m. BTK Refractory Mantle Cell Lymphoma
- Non-CAR-T – Tycel Jovelle Phillips, MD
- CAR-T – Marc S. Hoffmann, MD

9:00 a.m. Relapsed Primary CNS Lymphoma
- BTK-Based – Christopher R. D'Angelo, MD
- Chemo-Based – Kerry J. Savage, MD, MSc, FRCPC

Conference Agenda

All times are displayed in Hawaii Standard Time (HST)

The Masked Lymphoma Doctor
MODERATOR: Matthew A. Lunning, DO, FACP — 2

9:30 a.m. A Case of Peripheral T-Cell Lymphoma
Sonali M. Smith, MD
Julie M. Vose, MD, MBA
Kerry J. Savage, MD, MSc, FRCPC

10:00 a.m. A Case of Mantle Cell Lymphoma
Brad S. Kahl, MD
John P. Leonard, MD
Marc S. Hoffmann, MD

10:30 a.m. Refreshment Break — 1

MODERATORS: Matthew A. Lunning, DO, FACP and Julie M. Vose, MD, MBA — 2

10:50 a.m. James O. Armitage Lymphoma Clinical Investigator Award
Caron A. Jacobson, MD, MMSc

11:20 a.m. Oliver Press Memorial Lecture
Elaine S. Jaffe, MD

11:50 a.m. Bierman's Brain Trivia Pineapple Cup Finals

12:30 p.m. Adjourn

Ask the Experts — 3

3:00 p.m. DLBCL
MODERATOR: James O. Armitage, MD
Nancy L. Bartlett, MD
Jason R. Westin, MD, MS, FACP
Andrew D. Zelenetz, MD, PhD

4:00 p.m. cHL
MODERATOR: Julie M. Vose, MD, MBA
Ranjana H. Advani, MD
Stephen M. Ansell, MD, PhD
Craig H. Moskowitz, MD

5:00 p.m. Adjourn

Thursday, July 18

7:00 a.m. Continental Breakfast — 1

Royal Lymphoma Rumble
MODERATOR: Nitin Jain, MD — 2

7:30 a.m. BV-CHP in CD30 Expressing Non-Anaplastic Large Cell Lymphoma - T-Cell Lymphoma
For: Kerry J. Savage, MD, MSc, FRCPC
Against: Swaminathan P. Iyer, MD

8:00 a.m. Autologous Transplantation for Mantle Cell Lymphoma
For: Andrew D. Zelenetz, MD, PhD
Against: Martin H. Dreyling, MD, PhD

8:30 a.m. BTK Monotherapy for First Line Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
For: Danielle M. Brander, MD
Against: Matthew S. Davids, MD, MMSc

9:00 a.m. Optimal CAR-T Construct in 2026
Autologous: Jeremy S. Abramson, MD, MMSc
Allogeneic: Frederick L. Locke, MD

9:30 a.m. Refreshment Break — 1

Who Knows
MODERATOR: Vijaya Raj Bhatt, MBBS, MS — 2

9:50 a.m. Is There a Right Management of Bispecific Toxicities?
Community Perspective: Tara M. Graff, DO, MS
Academic Perspective: Sarah C. Rutherford, MD

10:20 a.m. Is There a Right Management of BTK and BCL-2 Refractory CLL/SLL?
Susan M. O'Brien, MD

10:40 a.m. Is There a Right Management of Extranodal Marginal Zone Lymphoma?
Emanuele Zucca, MD

11:00 a.m. Is There a Right Management of CPI & BV Refractory cHL?
John Kuruvilla, MD, FRCP

11:20 a.m. Is There a Right Management of Primary CNS Lymphoma?
Neurologist Perspective: Christian Grommes, MD
Oncologist Perspective: Christopher R. D'Angelo, MD

12:00 p.m. Adjourn

Ask the Experts — 3

3:00 p.m. PTCL
MODERATOR: Matthew A. Lunning, DO, FACP
Charles A. Enke, MD, FASTRO, FACR
Steven M. Horwitz, MD
Swaminathan P. Iyer, MD

4:00 p.m. Waldenström Macroglobulinemia/Multiple Myeloma
Moderator: Christopher R. D'Angelo, MD
R. Gregory Bociek, MD, MSc, FRCP(C)
Yi Lin, MD, PhD
Krina K. Patel, MD, MSc

5:00 p.m. Adjourn

7:00 p.m. Conference Dinner — Registered guests welcome. Name badge required. — 5

Friday, July 19

7:00 a.m.	Continental Breakfast	1
Management of Orphan Diseases: When and How MODERATOR: Russell J. McCulloh, MD		2
7:30 a.m.	When and How To Treat Gamma-Delta Hepatosplenic T-Cell Lymphoma Steven M. Horwitz, MD	
7:50 a.m.	When and How To Treat with Total Skin Electron Beam Therapy (TSEBT) in Mycosis Fungoides Charles A. Enke, MD, FASTRO, FACR	
8:10 a.m.	When and How To Treat Autoimmune Complications of CLL/SLL Danielle M. Brander, MD	
8:30 a.m.	When and How To Treat Richter's Disease Matthew S. Davids, MD, MMSc	
8:50 a.m.	When and How To Treat Burkitt Lymphoma Mark Roschewski, MD	
9:10 a.m.	When and How To Treat Checkpoint-Related Adverse Events Alex F. Herrera, MD	
9:30 a.m.	Break	1
The Class of the Future is Here MODERATOR: Matthew A. Lunning, DO, FACP		2
9:50 a.m.	Future Therapies: Cellular Therapies Nirav N. Shah, MD, MSHP	
10:20 a.m.	Future Therapies: Degraders & Celmods Marc S. Hoffmann, MD	
10:50 a.m.	Future Therapies: Bispecifics or X-Specific Antibodies Michael Dickinson, MD, PhD	
11:20 a.m.	Antibody Drug Conjugates Christopher R. D'Angelo, MD	
11:50 a.m.	Aloha/Conch Ceremony Matthew A. Lunning, DO, FACP	
12:00 p.m.	Adjourn	

Notes

Conference Faculty

Jeremy S. Abramson, MD, MMSc
Director, Jon and Jo Ann Hagler Center for Lymphoma, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, MA

Ranjana H. Advani, MD
Saul A. Rosenberg Professor of Lymphoma, Department of Medicine/Oncology, Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

Stephen M. Ansell, MD, PhD
Dorotha W. and Grant L. Sundquist Professor in Hematologic Malignancies Research; Chair, Division of Hematology, Mayo Clinic, Rochester, MN

James O. Armitage, MD★
Joe Shapiro Professor of Medicine, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD
Professor of PET Imaging and NIHR Research Professor, School of Biomedical Engineering and Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom

Nancy L. Bartlett, MD
Professor of Medicine, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO

Vijaya Raj Bhatt, MBBS, MS
Professor, Division of Oncology and Hematology; Medical Director, Leukemia Program Section Leader, Malignant Hematology, University of Nebraska Medical Center, Omaha, NE

Philip J. Bierman, MD
Professor Emeritus, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Ruemu E. Birhiray, MD
Clinical Professor of Medicine, Marian University, College of Osteopathic Medicine; Oncology Specialist, Hematology Oncology of Indiana, A Division of American Oncology Network, PA.; President/CEO, Indy Hematology Education, Inc., Indianapolis, IN

R. Gregory Bociek, MD, MSc, FRCP(C)
Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Danielle M. Brander, MD
Assistant Professor of Medicine; Director, CLL & Lymphoma Research Program, Member of the Duke Cancer Institute, Duke Health Integrated Practice, Durham, NC

Natalie S. Callander, MD
Professor of Medicine; Director, Myeloma Clinical Program, University of Wisconsin Carbone Cancer Center, Madison, WI

Bruce D. Cheson, MD, FACP, FAAAS, FASCO
Scientific Advisor to the Lymphoma Research Foundation; Center for Cancer and Blood Disorders, Bethesda, MD

Christine Cox, RN
Dana-Farber/Brigham & Women's Cancer Institute, Boston, MA

Sarah L. Creamer, MD
Hematologist/Medical Oncologist, Nebraska Cancer Specialists, Grand Island, NE

Christopher R. D'Angelo, MD
Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine, Harvard Medical School; Co-Leader, Lymphoma and Myeloma Program, Dana-Farber/Harvard Cancer Center; Clinical Research Director, Division of Lymphoma, Dana-Farber Cancer Institute, Boston, MA

Michael Dickinson, MD, PhD
Associate Professor and Lead of the Aggressive Lymphoma Disease Group, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia

Martin H. Dreyling, MD, PhD
Professor of Medicine, LMU University Hospital, Munich, Germany

Charles A. Enke, MD, FASTRO, FACR
Chairman and Professor, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE

Jonathan W. Friedberg, MD, MMSc
Director, James P. Wilmot Cancer Institute; Samuel Durand Professor of Medicine, University of Rochester Medical Center, Rochester, NY

Tara M. Graff, DO, MS
Physician Champion and Lead, Mission Cancer Trials Program, Mission Cancer and Blood, Des Moines, IA

Michael R. Green, PhD
Associate Professor; Director, Translational and Laboratory Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Christian Grommes, MD
Associate Member, Department of Neurology, Memorial Sloan Kettering Cancer Center; Associate Professor of Neurology, Weill Cornell Medical College, New York, NY

Alex F. Herrera, MD
Associate Professor; Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation; Associate Medical Director of the Briskin Center for Clinical Research & City of Hope Duarte Clinical Trials Office, City of Hope Medical Center, Duarte, CA

Marc S. Hoffmann, MD
Director, Lymphoma Program; Medical Director, Lean and Quality Improvement; Associate Professor, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS

Steven M. Horwitz, MD
Member and Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Swaminathan P. Iyer, MD
Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Caron A. Jacobson, MD, MMSc
Medical Director, Immune Effector Cell Therapy Program; Senior Physician; Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Elaine S. Jaffe, MD
NIH Distinguished Investigator, Head, Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Nitin Jain, MD
Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Brad S. Kahl, MD
Professor of Medicine; Director, Lymphoma Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

David S. Kroll, MD
Associate Vice Chair for Quality and Safety, Department of Psychiatry, Brigham and Women's Hospital; Director of Ambulatory Psychiatry, Mass General Brigham, Boston, MA

John Kuruvilla, MD, FRCP
Professor of Medicine, University of Toronto; Clinician Investigator, Princess Margaret Cancer Centre Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, Ontario, Canada

★ **Conference Director**

Ann S. LaCasce, MD, MMSc
Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology; Fellowship Program in Hematology/Oncology Chair; Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

John P. Leonard, MD
Senior Associate Dean for Innovation and Initiatives; Chair (Interim), Weill Department of Medicine; Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medicine and New York-Presbyterian, New York, NY

Yi Lin, MD, PhD
Professor of Medicine; Assistant Professor of Oncology, Mayo Clinic College of Medicine, Rochester, MN

Frederick L. Locke, MD
Moffit Distinguished Scholar and Hawkins Family Endowed Chair; Department Chair and Senior Member, Blood and Marrow Transplant and Cellular Immunotherapy; Leader, Cellular Immunotherapy Program, Moffitt Medical Group; Co-Leader, Immuno-Oncology Program, Moffitt Research Institute; Professor, Oncological Sciences, University of South Florida, Tampa, FL

Matthew A. Lunning, DO, FACP★
Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine; Assistant Vice Chancellor for Clinical Research, University of Nebraska Medical Center, Omaha, NE

Kami J. Maddocks, MD
Professor, Division of Hematology; Director, Lymphoma Program; Medical Director of Infusion Services, The Ohio State University James Comprehensive Cancer Center, Columbus, OH

Jared E. Matya, PharmD, BCOP
Clinical Pharmacist Practitioner, Blood and Marrow Transplant/Cellular Therapy, Nebraska Medicine, Omaha, NE

Russell J. McCulloh, MD
Vice President for Research, Nebraska Medicine; Associate Vice Chancellor for Clinical Research; Professor, Division of Hospital Medicine; Professor, Department of Pediatrics, Division of Infectious Diseases; University of Nebraska Medical Center, Omaha, NE

Angela Mortensen, LICSW
Social Worker, Nebraska Medicine, Omaha, NE

Craig H. Moskowitz, MD
Physician-in-Chief, Cancer Service Line, Sylvester Comprehensive Cancer Center; Professor of Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL

Caitlin A. Murphy DNP, APRN, FNP-BC, AOCNP
Clinical Nurse Practitioner, Dana-Farber Cancer Institute, Boston, MA

Grzegorz S. Nowakowski, MD
Associate Professor, Department of Hematology and Oncology, Mayo Clinic, Rochester, MN

Susan M. O'Brien, MD
Professor of Medicine; Division of Hematology/ Oncology, University of California/Irvine, Irvine, CA

Krina K. Patel, MD, MSc
Associate Professor, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Katie Penas, MHA, CNMT, RT(N)
Clinical Research Manager, Clinical Research Center, Nebraska Medicine, Omaha, NE

Tycel Jovelle Phillips, MD
Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Mark Roschewski, MD
Senior Clinician and the Clinical Director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research, National Cancer Institute Center for Cancer Research, National Institutes of Health, Bethesda, MD

Davide Rossi, MD, PhD
Group Leader, Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland; Deputy Head, Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Co-chair, Lymphoma Research Program, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Associate Professor, Faculty of Biomedical Sciences, Universita' della Svizzera italiana, Lugano, Switzerland

Sarah C. Rutherford, MD
Associate Professor of Clinical Medicine, Division of Hematology/Oncology, Weill Cornell Medical Center Sandra and Edward Meyer Cancer Center, New York, NY

Gilles Salles, MD, PhD
Service Chief, Lymphoma Service, Steven A. Greenberg Chair, Memorial Sloan Kettering Cancer Center, New York, NY

Craig S. Sauter, MD
Director, Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH

Kerry J. Savage, MD, MSc, FRCPC
Professor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer, Vancouver, British Columbia, Canada

Ashley L. Schmitt, PA-C
Nebraska Medicine, Omaha, NE

Nirav N. Shah, MD, MSHP
Associate Professor of Medicine, Lymphoma/BMT Program, Medical College of Wisconsin, Milwaukee, WI

Kyle Skiermont, PharmD
Assistant Dean for Clinical Affairs, College of Pharmacy, University of Nebraska Medical Center; Vice President of Pharmacy and Oncology, Nebraska Medicine, Omaha, NE

Sonali M. Smith, MD
Elwood V. Jensen Professor of Medicine; Chief, Section of Hematology/ Oncology; Co-Director, Lymphoma Program, The University of Chicago, Chicago, IL

Joann B. Sweasy, PhD
Director, Fred & Pamela Buffett Cancer Center; Director, UNMC Eppley Institute for Research in Cancer and Allied Diseases; Professor, Eppley Institute, University of Nebraska Medical Center, Omaha, NE

Judith Trotman, MBChB, FRACP, FRCPA
Clinical Professor, University of Sydney; Head of Department, Haematology, Concord Repatriation General Hospital, Concord, Australia

Julie M. Vose, MD, MBA★
Neumann M. and Mildred E. Harris Professor and Chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Michael Wang, MD
Puddin Clarke Endowed Professor, Director, Mantle Cell Lymphoma Program of Excellence; Co-Director, B-Cell Lymphoma Moon Shot Program; Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Jason R. Westin, MD, MS, FACP
Professor; Section Chief, Aggressive Lymphoma; Director, Lymphoma Clinical Research Program, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics; Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medicine, New York, NY

Emanuele Zucca, MD
Consultant and Head of the Lymphoma Unit, Division of Medical Oncology, The Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

Education Information

Target Audience

The 2024 Pan Pacific Lymphoma Conference will benefit members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, advanced practice providers, nurses, and pharmacists.

Conference Objectives

At the conclusion of the conference, the participant should be better able to:

1. Provide an update on biosimilar and generic medications utilized in the management of lymphoma.
2. Discuss the recognition of adverse events in new and emerging therapies in lymphoma that may result in dose reductions or dose holds in the management of lymphoma.
3. Identify the best utilization of rehabilitation facilities in the care of patients with lymphoma.
4. Discuss the optimal makeup and strategies for optimal clinic efficiency in a lymphoma-specific clinic.
5. Discuss how to optimally conduct and operationalize clinical trials for all potential subjects.
6. Identify factors related to anxiety, depression, and substance abuse amongst providers and the impact on their well-being.
7. Describe the key alterations that lead to lymphoma, how artificial intelligence may impact the pathological pathway to diagnosis of lymphoma, and how liquid tumor biopsy may supplement the response to therapy analysis.
8. Discuss how the evolving imaging technologies may be integrated into response assessment in the management of lymphoma.
9. Assess the impact of past and future therapies for the initial treatment of classical Hodgkin lymphoma (cHL), large B-cell lymphoma (LBCL), and mantle cell lymphoma (MCL).
10. Evaluate the diverse landscape of monoclonal gammopathies of unknown significance, treatment for lymphoplasmacytic lymphoma (LPL), and novel treatment for plasma cell dyscrasias (PCD).
11. Analyze clinical trial results impacting the management of relapsed and/or refractory follicular lymphoma (FL), peripheral T-cell lymphoma (PTCL), LBCL, MCL, and primary central nervous system lymphoma (PCNSL).
12. Differentiate the treatment options for CD30+ PTCL.
13. Discuss the changing role of consolidative autologous transplantation in MCL.
14. Discuss the optimal initial and relapsed/refractory sequencing for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
15. Discuss optimal treatment and management of marginal zone lymphoma (MZL), CLL/SLL, PTCL, and MCL complications.
16. Explain the roles of the interprofessional health care team in the diagnosis, treatment, management, and support of lymphoma and hematologic malignancies.

Continuing Education Credits

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 28.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

The University of Nebraska Medical Center designates this activity for up to 28.0 ANCC contact hours. Nurses should only claim credit for the actual time spent in the activity.

PHARMACISTS

The University of Nebraska Medical Center designates this activity for 28.0 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

28.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

28.0 MOC points in the American Board of Pathology's (ABPATH) Maintenance of Certification (MOC) program.

It is the CME Provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

We gratefully acknowledge the following for financial support of this conference:

PLATINUM SUPPORTER
AstraZeneca Pharmaceuticals

GOLD SUPPORTER
BeiGene USA, Inc.

SILVER SUPPORTERS
Eli Lilly & Company
Pfizer Oncology

BRONZE SUPPORTERS
Genmab US, Inc.

COPPER SUPPORTERS
AbbVie, Inc.
Acrotech Biopharma, Inc.
Bristol Myers Squibb Company
BTG Pharmaceuticals
Citius Pharmaceuticals
Genentech, Inc.
GlaxoSmithKline LLC
Incyte Corporation
Kite Pharma, Inc.
Merck & Co, Inc.
Pharmacyclics, LLC
Recordati Rare Diseases, Inc.
Sobi

EDUCATIONAL GRANTS
AbbVie, Inc.
AstraZeneca Pharmaceuticals
BTG Pharmaceuticals
Genentech, Inc.
Ipsen
Eli Lilly & Company
Novartis Pharmaceuticals Corporation

How to Claim Continuing Education Credit

To obtain continuing education credit, you must complete the general and session evaluations.

- On your mobile phone or tablet, sign in to the conference app and click the Claim Credit/MOC/Conference Evaluation tile.
- Using a laptop or desktop, sign in to the conference portal and go to Claim Credit/MOC/Conference Evaluation.

Please make sure to update your account profile information.

FOR PHYSICIANS CLAIMING AMA AND MOC CREDIT:
- Complete the pretest for MOC credit
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Complete the post test for MOC credit
- Retrieve your certificate

FOR PHYSICIANS AND OTHER HEALTH CARE PROVIDERS CLAIMING AMA OR ANCC CREDIT:
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Retrieve your certificate

FOR PHARMACISTS CLAIMING ACPE CREDIT:
- Make sure your date of birth (mm/dd) and NABP ID# are entered in your profile. (Your NABP ID# is different from your license number)
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation

You have up to **September 15, 2024** to complete the evaluation and claim credit for participation.

Disclosure Information

Disclosure Declaration

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC-accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

THE FOLLOWING FACULTY MEMBERS HAVE DISCLOSED RELEVANT FINANCIAL RELATIONSHIPS:

Jeremy S. Abramson, MD, MMSc
CONSULTANT: AbbVie Inc., AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Gilead Sciences/Kite Pharma, Interius, Pfizer/Seagen, Takeda
UNIVERSITY GRANTS/RESEARCH SUPPORT: Bristol Myers Squibb, Cellectis, Merck, Mustang Bio, Pfizer/Seagen

Ranjana H. Advani, MD
ADVISORY BOARD: BeiGene, Inc., Genentech/Roche
GRANT/RESEARCH SUPPORT: BeiGene, Inc., Cyteir, Daiichi Sankyo, Genentech/Roche, Gilead Sciences, Merck, Regeneron, Pfizer/Seagen

Stephen M. Ansell, MD, PhD
UNIVERSITY GRANTS/RESEARCH SUPPORT: ADC Therapeutics, Affimed, AstraZeneca, Bristol Myers Squibb, Pfizer, Regeneron, Pfizer/Seagen, Takeda

James O. Armitage, MD[1]
ADVISORY BOARD: Syncromune
BOARD MEMBER: Cardiff Oncology

Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD
GRANT/RESEARCH SUPPORT: AstraZeneca, BeiGene, Inc., Takeda/Millennium

Nancy L. Bartlett, MD
ADVISORY BOARD: ADC Therapeutics, Foresight Diagnostics, Genmab, Genentech/Roche, Pfizer/Seagen
GRANT/RESEARCH SUPPORT: ADC Therapeutics, Autolus, Bristol Myers Squibb/Celgene Corporation, Forty Seven, Inc., Genentech/Roche, Gilead Sciences/Kite Pharma, Janssen, Merck, Millenium, Pharmacyclics LLC (an AbbVie company), Pfizer/Seagen

Vijaya Raj Bhatt, MBBS, MS
ADVISORY BOARD: Protagonist
CONSULTANT: Imugene, Sanofi U.S. Services, Taiho
CONTRACTED RESEARCH: MEI Pharmaceuticals, National Marrow Donor Program, Sanofi U.S. Services
GRANT/RESEARCH SUPPORT: AbbVie Inc., Actinium Pharmaceuticals, Incyte Corp., Jazz Pharmaceuticals, Pfizer
OTHER FINANCIAL OR MATERIAL SUPPORT: Chimerix

Ruemu E. Birhiray, MD
ADVISORY BOARD: AbbVie Inc., Amgen, Bristol Myers Squibb, GSK, Incyte Corp., Johnson and Johnson, Regeneron
BOARD MEMBER: AbbVie Inc., Amgen, Bristol Myers Squibb, GSK, Incyte Corp., Johnson and Johnson, Regeneron
CONSULTANT: AbbVie Inc., Amgen, Bristol Myers Squibb, GSK, Incyte Corp., Johnson and Johnson, Regeneron
CONTRACTED RESEARCH: Regeneron
HONORARIUM RECIPIENT: AbbVie Inc., Amgen, Bristol Myers Squibb, GSK, Incyte Corp., Johnson and Johnson, Regeneron

R. Gregory Bociek, MD, MSc, FRCP(C)
ADVISORY BOARD: Innate Pharma

Danielle M. Brander, MD
CONSULTANT: AbbVie Inc., Genentech/Roche
UNIVERSITY GRANTS/RESEARCH SUPPORT: AbbVie Inc., Acerta/AstraZeneca, BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Catapult, Genentech/Roche, Merck, NeWave, Nurix, Pharmacyclics LLC (an AbbVie company)

Bruce D. Cheson, MD, FACP, FAAAS, FASCO
ADVISORY BOARD: BeiGene, Inc., Regeneron
BOARD MEMBER: Symbio
CONSULTANT: AbbVie Inc., Calyx, Imaging Endpoints, Janssen/Pharmacyclics LLC (an AbbVie company), Eli Lilly and Company
OTHER FINANCIAL OR MATERIAL SUPPORT: BeiGene, Inc., Eli Lilly and Company

Christopher R. D'Angelo, MD

ADVISORY BOARD: AbbVie Inc., Bristol Myers Squibb, Curis Inc., Ono Pharmaceutical Co., Ltd., Pfizer/Seagen

CONSULTANT: AbbVie Inc.

GRANT/RESEARCH SUPPORT: AbbVie Inc., BeiGene, Inc., Bristol Myers Squibb, Curis Inc., Fate Therapeutics, Ono Pharmaceutical Co., Ltd.

Matthew S. Davids, MD, MMSc

CONSULTANT: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genentech/Roche, Genmab, Janssen, Merck, Nuvalent, SecuraBio, Takeda

GRANT/RESEARCH SUPPORT: Ascentage Pharma, MEI Pharmaceuticals, Novartis

Michael Dickinson, MD, PhD

ADVISORY BOARD: AbbVie Inc., Genentech/Roche, Gilead Sciences/Kite Pharma, Novartis

BOARD MEMBER: AbbVie Inc.

CONSULTANT: AbbVie Inc., Genentech/Roche, Gilead Sciences/Kite Pharma, Novartis

CONTRACTED RESEARCH: AbbVie Inc., Genentech/Roche, Gilead Sciences/Kite Pharma

GRANT/RESEARCH SUPPORT: AbbVie Inc., Genentech/Roche, Gilead Sciences/Kite Pharma, Novartis

HONORARIUM RECIPIENT: AbbVie Inc., Genentech/Roche, Gilead Sciences/Kite Pharma, Novartis

UNIVERSITY GRANTS/RESEARCH SUPPORT: AbbVie Inc., Genentech/Roche, Gilead Sciences/Kite Pharma

Martin H. Dreyling, MD, PhD

ADVISORY BOARD: AbbVie Inc., AstraZeneca, BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Eli Lilly and Company, Gilead Sciences/Kite Pharma, Janssen, Novartis, Roche

GRANT/RESEARCH SUPPORT: Bayer, Bristol Myers Squibb/Celgene Corporation, Eli Lilly and Company, Gilead Sciences/Kite Pharma, Janssen

HONORARIUM RECIPIENT: AstraZeneca, BeiGene, Inc., Eli Lilly and Company, Janssen, Novartis, Roche

UNIVERSITY GRANTS/RESEARCH SUPPORT: AbbVie Inc.

Tara M. Graff DO, MS

ADVISORY BOARD: AbbVie Inc., Acerta/AstraZeneca, ADC Therapeutics, BeiGene, Inc., Bristol Myers Squibb, Cellectar, Eli Lilly and Company, Genentech/Roche, Genmab, MorphoSys US

CONSULTANT: Adaptive Biotechnologies, Cellectar, Genentech/Roche, Genmab

HONORARIUM RECIPIENT: AbbVie Inc., Acerta/AstraZeneca, Adaptive Biotechnologies, ADC Therapeutics, BeiGene, Inc., Bristol Myers Squibb, Cellectar, Eli Lilly and Company, Genentech/Roche, Genmab, Gilead Sciences/Kite Pharma, MorphoSys US

Michael R. Green, PhD

GRANT/RESEARCH SUPPORT: Allogene, Sanofi

Christian Grommes, MD

CONSULTANT: Curis, Ono Pharmaceutical Co., Ltd., Genentech/Roche

Alex F. Herrera, MD

CONSULTANT: AbbVie Inc., ADC Therapeutics, Adicet Bio, Allogene, AstraZeneca, Pfizer/Seagen, Takeda, Tubulis

GRANT/RESEARCH SUPPORT: ADC Therapeutics, AstraZeneca, Pfizer/Seagen

Marc S. Hoffmann, MD

ADVISORY BOARD: Novartis

CONSULTANT: ADC Therapeutics, AstraZeneca, BeiGene, Inc., Genentech/Roche, Novartis

GRANT/RESEARCH SUPPORT: Genentech/Roche

HONORARIUM RECIPIENT: AbbVie Inc., ADC Therapeutics, AstraZeneca, BeiGene, Inc., Genentech/Roche, Novartis

Steven M. Horwitz, MD

CONSULTANT: Abcuro Inc., Autolus, Auxilius Pharma, Corvus Pharma, Daiichi Sankyo, Dren Bio, Kyowa Hakko Kirin Pharma, March Bio, Ono Pharmaceutical Co., Ltd., SecuraBio, Takeda

GRANT/RESEARCH SUPPORT: ADC Therapeutics, Affimed, Celgene Corporation/Acceleron, Crispr, Daiichi Sankyo, Kyowa Hakko Kirin Pharma, Pfizer/Seagen, SecuraBio, Takeda, Trillium Therapeutics, Inc.

Caron A. Jacobson, MD, MMSc

ADVISORY BOARD: AbbVie Inc., Janssen

CONSULTANT: AbbVie Inc., Bristol Myers Squibb/Celgene Corporation, Janssen, Gilead Sciences/Kite Pharma, Novartis

CONTRACTED RESEARCH: Gilead Sciences/Kite Pharma

GRANT/RESEARCH SUPPORT: Gilead Sciences/Kite Pharma

HONORARIUM RECIPIENT: Gilead Sciences/Kite Pharma

Nitin Jain, MD

ADVISORY BOARD: AbbVie Inc., Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Autolus, BeiGene, Inc., Bristol Myers Squibb, Eli Lilly and Company, Genentech/Roche, Gilead Sciences/Kite Pharma, Janssen/Pharmacyclics LLC (an AbbVie company), MingSight, Novalgen

CONSULTANT: AbbVie Inc., Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Autolus, BeiGene, Inc., Bristol Myers Squibb, Eli Lilly and Company, Genentech/Roche, Gilead Sciences/Kite Pharma, Janssen/Pharmacyclics LLC (an AbbVie company), MingSight, Novalgen

CONTRACTED RESEARCH: AbbVie Inc., Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Carna Biosciences, Cellectis, Eli Lilly and Company, Fate Therapeutics, Genentech/Roche, Gilead Sciences/Kite Pharma, Janssen/Pharmacyclics LLC (an AbbVie company), MingSight, NeWave, Novalgen, Novartis, Precision Biosciences, Sana Biotechnology, Takeda

GRANT/RESEARCH SUPPORT: AbbVie Inc., Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Carna Biosciences, Cellectis, Eli Lilly and Company, Fate Therapeutics, Genentech/Roche, Gilead Sciences/Kite Pharma, Janssen/Pharmacyclics LLC (an AbbVie company), MingSight, NeWave, Novartis, Precision Biosciences, Sana Biotechnology, Takeda

HONORARIUM RECIPIENT: AbbVie Inc., Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Autolus, BeiGene, Inc., Bristol Myers Squibb, Eli Lilly and Company, Genentech/Roche, Gilead Sciences/Kite Pharma, Janssen/Pharmacyclics LLC (an AbbVie company), MingSight

Disclosure Information

Brad S. Kahl, MD
ADVISORY BOARD: AbbVie Inc., AstraZeneca, BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Eli Lilly and Company, Genentech/Roche, Gilead Sciences/Kite Pharma, GSK, Merck, Novartis

John Kuruvilla, MD, FRCPC
CONSULTANT: AbbVie Inc., AstraZeneca, Bristol Myers Squibb/Celgene Corporation, Incyte Corp., Gilead Sciences/Kite Pharma, Merck, Novartis, Pfizer/Seagen, Roche
GRANT/RESEARCH SUPPORT: AstraZeneca, Gilead Sciences/Kite Pharma, Merck, Novartis, Roche
HONORARIUM RECIPIENT: AbbVie Inc., Amgen, AstraZeneca, BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Genmab, Incyte Corp., Janssen, Gilead Sciences/Kite Pharma, Merck, Novartis, Pfizer/Seagen, Roche

Ann S. LaCasce, MD, MMSc
ADVISORY BOARD: Kite Pharma, Pfizer/Seagen
HONORARIUM RECIPIENT: Research to Practice

John P. Leonard, MD
CONSULTANT: AbbVie Inc., Astellas, AstraZeneca, Bayer, BeiGene, Inc., Bristol Myers Squibb, Calithera, Caribou Biosciences, Constellation Pharmaceuticals, Eisai, Eli Lilly and Company, Epizyme, Genentech/Roche, Genmab, Incyte Corp., Janssen, MEI Pharmaceuticals, Merck Sharp & Dohme Corp., Mustang Bio, Novartis, Pfizer, Pharmacyclics LLC (an AbbVie company), Regeneron, Pfizer/Seagen, Second Genome, Sutro, Treeline Biosciences
CONTRACTED RESEARCH: Epizyme, Janssen
GRANT/RESEARCH SUPPORT: Genentech/Roche

Yi Lin, MD, PhD
ADVISORY BOARD: Bristol Myers Squibb, Caribou, Genentech/Roche, Janssen, NexImmune, Pfizer, Regeneron, Sanofi
GRANT/RESEARCH SUPPORT: Bristol Myers Squibb, Janssen

Frederick L. Locke, MD
ADVISORY BOARD: A2 Biotherapeutics, Allogene, Amgen, Bluebird Bio, Bristol Myers Squibb, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Janssen, Kite Pharma, Legend Biotech, Novartis, Pfizer, Sana, Umoja
CONSULTANT: A2 Biotherapeutics, Allogene, Amgen, Bluebird Bio, Bristol Myers Squibb, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Janssen, Kite Pharma, Legend Biotech, Novartis, Pfizer, Sana, Umoja
GRANT/RESEARCH SUPPORT: 2SeventyBio, Allogene, Bluebird Bio, Bristol Myers Squibb, CERo Therapeutics, Kite Pharma, Leukemia and Lymphoma Society, National Cancer Institute, Novartis
OTHER FINANCIAL OR MATERIAL SUPPORT: American Society of Hematology, Aptitude Health, BioPharma Communications, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer

Matthew A. Lunning, DO, FACP[2]
CONSULTANT: AbbVie Inc., Acrotech Biopharma, ADC Therapeutics, Bristol Myers Squibb, Caribou Biosciences, CRISPR, Daiichi Sankyo, Fate Therapeutics, Genentech/Roche, Genmab, Incyte Corp., Ipsen Biopharmaceuticals, Janssen, Kite Pharma, Loxo Oncology, Nurix, Recordati, Regeneron, Sanofi, Pfizer/Seagen, VITToria
GRANT/RESEARCH SUPPORT: Bristol Myers Squibb, Fate Therapeutics, Sana Therapeutics
HONORARIUM RECIPIENT: AbbVie Inc., Acrotech Biopharma, ADC Therapeutics, Bristol Myers Squibb, Caribou Biosciences, CRISPR, Daiichi Sankyo, Fate Therapeutics, Genentech/Roche, Genmab, Incyte Corp., Ipsen Biopharmaceuticals, Janssen, Kite Pharma, Loxo Oncology, Nurix, Recordati, Regeneron, Sanofi, Pfizer/Seagen, VITToria

Kami J. Maddocks, MD
CONSULTANT: AbbVie Inc., ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Genentech/Roche, Genmab, Incyte Corp., Janssen, Kite Pharma, MorphoSys US

Jared E. Matya, PharmD, BCOP
ADVISORY BOARD: Acerta/AstraZeneca, BTG
HONORARIUM RECIPIENT: BTG, Medscape

Craig H. Moskowitz, MD
ADVISORY BOARD: ADC Therapeutic, AstraZeneca, Incyte Corp., Pfizer/Seagen, Merck, Takeda, Merck

Grzegorz S. Nowakowski, MD
ADVISORY BOARD: AbbVie Inc., ADC Therapeutics, Bantam Pharmaceutical, LLC, Daiichi Sankyo, Fate Therapeutics, Incyte Corp., Karyopharm Therapeutics, Kite Pharma, Kymera, MEI Pharma, TG Therapeutics
CONSULTANT: Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Constellation Pharmaceuticals, Curis, Debiopharm, F Hoffman-La Roche Limited, Genentech/Roche, MorphoSys US, Ryvu Therapeutics, Pfizer/Seagen, Selvita, Zai Laboratory

Susan M. O'Brien, MD
CONSULTANT: AbbVie Inc., AstraZeneca, Autolus, BeiGene, Inc., Bristol Myers Squibb, Eli Lilly and Company, GSK, Janssen, Johnson & Johnson, Loxo Oncology, Merck, Pfizer, Pharmacyclics LLC (an AbbVie company), TG Therapeutics, Vanium Group LLC
CONTRACTED RESEARCH: Pharmacyclics LLC (an AbbVie company)
GRANT/RESEARCH SUPPORT: Alliance, AstraZeneca, Caribou Biosciences, Gilead Sciences, Inc, Kite Pharma, Mustang Bio, Nurix Therapeutics Inc., Pfizer, Regeneron, TG Therapeutics

Krina K. Patel, MD, MSc
CONSULTANT: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Curio Sciences Bio, Janssen, Legend Biotech, Merck, Oncopeptides, Karyopharm Therapeutics, Pfizer, PrecisionBio
GRANT/RESEARCH SUPPORT: Abbvie, Allogene, Arcellx, Bristol Myers Squibb, Celgene, Cellectis, Janssen, Nektar, Poseida, Precision Bio, Takeda

Tycel Jovelle Phillips, MD

ADVISORY BOARD: AbbVie Inc., Acerta/AstraZeneca, Adaptive Biotechnologies, ADC Therapeutics, BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Eli Lilly and Company, Epizyme, Inc., Genentech/Roche, Genmab A/S, Gilead Sciences/Kite Pharma, Ipsen, Janssen, Merck, Pharmacyclics LLC (an AbbVie company), Xencor

CONSULTANT: AbbVie Inc., Acerta/AstraZeneca, Bristol Myers Squibb/Celgene Corporation, Genentech/Roche, Genmab A/S, Merck, Pharmacyclics LLC (an AbbVie company)

CONTRACTED RESEARCH: Bristol Myers Squibb/Celgene Corporation, Genentech/Roche

GRANT/RESEARCH SUPPORT: AbbVie Inc., Cures Within Reach, Genentech/Roche, Leukemia and Lymphoma Society, Sobi

Davide Rossi, MD, PhD

GRANT/RESEARCH SUPPORT: AbbVie Inc., AstraZeneca, BeiGene, Inc., Janssen

HONORARIUM RECIPIENT: AbbVie Inc., AstraZeneca, BeiGene, Inc., Bristol Myers Squibb

OTHER FINANCIAL OR MATERIAL SUPPORT: AstraZeneca, Janssen

Sarah C. Rutherford, MD

CONSULTANT: ADC Therapeutics, Bristol Myers Squibb, Genmab, Karyopharm Therapeutics, Kite Pharma, Pfizer/Seagen

GRANT/RESEARCH SUPPORT: Constellation Pharmaceuticals, Genentech/Roche, Karyopharm Therapeutics

Gilles Salles, MD, PhD

ADVISORY BOARD: AbbVie Inc., BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Genentech/Roche, Genmab, Incyte Corp., Innate Pharma, Ipsen, Janssen, Kite Pharma, Merck, Novartis, Nurix

CONSULTANT: AbbVie Inc., Atbtherapeutics, Bristol Myers Squibb/Celgene Corporation, Genentech/Roche, Modex, Novartis

GRANT/RESEARCH SUPPORT: AbbVie Inc., Genentech/Roche, Ipsen, Janssen, Nurix

HONORARIUM RECIPIENT: BeiGene, Inc., Kite Pharma, Merck

Kerry J. Savage, MD, MSc, FRCPC

ADVISORY BOARD: Bristol Myers Squibb, Pfizer/Seagen

BOARD MEMBER: Regeneron

CONSULTANT: Bristol Myers Squibb, Pfizer/Seagen

GRANT/RESEARCH SUPPORT: Bristol Myers Squibb

HONORARIUM RECIPIENT: Pfizer/Seagen

Ashley L. Schmitt, PA-C

ADVISORY BOARD: Pfizer/Seagen

Nirav N. Shah, MD, MSHP

ADVISORY BOARD: Bristol Myers Squibb, Eli Lilly and Company, Galapagos, Kite Pharma, Miltenyi Biomedicine, Pfizer/Seagen

CONSULTANT: AbbVie Inc., Eli Lilly and Company, Miltenyi Biomedicine

CONTRACTED RESEARCH: Eli Lilly and Company, Miltenyi Biomedicine

GRANT/RESEARCH SUPPORT: Eli Lilly and Company, Miltenyi Biomedicine

HONORARIUM RECIPIENT: Miltenyi Biomedicine

Kyle Skiermont, PharmD

HONORARIUM RECIPIENT: BeiGene, Inc.

Sonali M. Smith, MD

OTHER FINANCIAL OR MATERIAL SUPPORT: Caris Life Sciences

Judith Trotman, MBChB, FRACP, FRCPA

GRANT/RESEARCH SUPPORT: BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Cellectar, Roche

Julie M. Vose, MD, MBA[3]

HONORARIUM RECIPIENT: AbbVie Inc., Adaptive, Foresight Diagnostics, Genmab, MEI Pharma

Michael Wang, MD

CONSULTANT: AbbVie, Acerta Pharma, ADC Therapeutics America, Amphista Therapeutics Limited, AstraZeneca, BeiGene, Inc., bE Biopharma, BioInvent, Bristol Myers Squibb, Deciphera, Eli Lilly and Company, Genentech/Roche, InnoCare, Janssen, Kite Pharma, Merck, Miltenyi Biomedicine, Oncternal

HONORARIUM RECIPIENT: AbbVie, Acerta Pharma, AstraZeneca, BeiGene, Inc., BioInvent, Bristol Myers Squibb, CAHON, Catamount Medical Education, Dava Oncology, Genmab, Janssen, Kite Pharma, MJH Life Sciences, Merck, MSC National Research Institute of Oncology, NIH, Nurix, Pharmacy

GRANT/RESEARCH SUPPORT: Acerta Pharma, AstraZeneca, BeiGene, Inc., BioInvent, Celgene Corporation, Genmab, Genentech/Roche, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Eli Lilly and Company, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics LLC (an AbbVie company), Vincerx

Jason R. Westin, MD, MS, FACP

ADVISORY BOARD: AbbVie Inc., ADC Therapeutics

CONSULTANT: AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Genmab, Janssen, Kite Pharma, Merck, MorphoSys US, Novartis, Regeneron, Pfizer/Seagen

GRANT/RESEARCH SUPPORT: ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Janssen, Kite Pharma, MorphoSys US, Novartis

Andrew D. Zelenetz, MD, PhD

CONSULTANT: AbbVie Inc., Adaptive Biotechnologies, Amgen, AstraZeneca, Celgene Corporation, Genentech/Roche/Roche, Gilead Sciences, Janssen, Mei Pharma, MorphoSys US, Novartis

GRANT/RESEARCH SUPPORT: BeiGene, Inc., Genentech/Roche, MEI Pharma, SPORE-PI

OTHER FINANCIAL OR MATERIAL SUPPORT: BeiGene, Inc., DMC Chair: Bristol Myers Squibb/Celgene Corporation/Juno-DMC Member

Emanuele Zucca, MD

ADVISORY BOARD: BeiGene, Inc., Incyte Corp., Janssen, Merck, Roche

GRANT/RESEARCH SUPPORT: AstraZeneca, BeiGene, Inc., Bristol Myers Squibb/Celgene Corporation, Incyte Corp., Janssen, Roche

OTHER FINANCIAL OR MATERIAL SUPPORT: AstraZeneca, Janssen, Merck, Roche

Disclosure Information

THE FOLLOWING FACULTY MEMBERS HAVE DISCLOSED OFF-LABEL, EXPERIMENTAL OR INVESTIGATIONAL USE OF DRUGS:

R. Gregory Bociek, MD, MSc, FRCP(C)
Off-label use discussion regarding data from ongoing clinical trials

Natalie S. Callander, MD
Off-label use discussed for smoldering myeloma: Lenalidomide, Daratumumab

Matthew S. Davids, MD, MMSc
Off-label use discussed: Ibrutinib, Acalabrutinib, Zanubrutinib, Obinutuzumab, Venetoclax, Pirtobrutinib

Michael Dickinson, MD, PhD
Off-label use for Lymphoma outside DLBCL or in combination - Glofitamab
Off-label use for Lymphoma outside of DLBCL / FL or in combination - Epcoritamab

Martin H. Dreyling, MD, PhD
Off-label use for MCL (first line) - Ibrutinib

John P. Leonard, MD
Off-label use for investigational lymphoma therapy

Susan M. O'Brien, MD
Off-label use for refractory CLL - Epcoritamb

Tycel Jovelle Phillips, MD
Off-label use for treatment of MCL - Glofitamab, mosunetuzumab/polatuzumab, venetoclax

Nirav N. Shah MD, MSHP
Off-label use of Novel CAR-T cells

THE FOLLOWING FACULTY MEMBERS HAVE NO FINANCIAL RELATIONSHIPS TO DISCLOSE:

Philip J. Bierman, MD
Natalie S. Callander, MD
Christine Cox, RN
Sarah L. Creamer, MD
Charles A. Enke, MD, FASTRO, FACR
Jonathan W. Friedberg MD, MMSc
Swaminathan P. Iyer, MD
Elaine S. Jaffe, MD
David S. Kroll, MD
Russell J. McCulloh, MD
Angela Mortensen, LICSW
Caitlin A. Murphy, DNP, APRN, FNP-BC, AOCNP
Katie Penas, MHA, CNMT, RT(N)
Mark Roschewski, MD
Craig S. Sauter, MD
Joann B. Sweasy, PhD

THE FOLLOWING PLANNING COMMITTEE MEMBERS HAVE FINANCIAL RELATIONSHIPS TO DISCLOSE:

James O. Armitage, MD[1]
Matthew W. Lunning, DO, FACP[2]
Julie M. Vose, MD, MBA[3]

THE FOLLOWING PLANNING COMMITTEE MEMBERS HAVE NO FINANCIAL RELATIONSHIPS TO DISCLOSE:

Jared E. Matya, PharmD, BCOP
Renee Paulin, MSN, RN, CWOCN
Brenda Ram, CMP, CHCP

[1]Financial relationships noted on pages 16.
[2]Financial relationships noted on pages 18.
[3]Financial relationships noted on pages 19.

PRODUCT THEATER
KAUAI BALLROOM

Tuesday, July 16, 2024

6-7 a.m.

Long-Term Clinical Data From Multiple Phase 3 Trials for CALQUENCE in the Treatment of CLL/SLL

TARA GRAFF, DO

Hematologist/Oncologist
Mission Blood and Cancer
Des Moines, Iowa

PRODUCT THEATER SUPPORTED BY:

AstraZeneca

July 15-19 | MAUI, HAWAII

#PPLC24 #IamUNMC

THIS PRODUCT THEATER PRESENTS CLINICAL EFFICACY AND SAFETY DATA SUPPORTING THE USE OF A SELECTIVE BRUTON TYROSINE KINASE INHIBITOR FOR THE TREATMENT OF PREVIOUSLY UNTREATED AND R/R CLL

Exhibitors

Exhibit Hall

Grand Promenade



1. **AbbVie, Inc.** is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people, and unique approach to innovation to improve treatments across four therapeutic areas: immunology, oncology, virology, and neuroscience. Follow @abbvie on X, Facebook, and LinkedIn, or visit www.abbvie.com.

2. **Acrotech Biopharma, Inc.** Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient-focused, research-based organization that strives to launch treatments which are accessible to patients who need them.

3. **AstraZeneca Pharmaceuticals** is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapeutic areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on X @AstraZenecaUS.

4. **BeiGene USA, Inc.** is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting the development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations.

5. **Bristol Myers Squibb Company** is a leading global biopharma company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis, and neuroscience. Our employees work every day to transform patients' lives through science.

6. **BTG Pharmaceuticals**, a SERB company, is dedicated to helping healthcare providers treat patients with critical conditions, focusing on emergency care and rare diseases.

7. **Citius Pharmaceuticals** is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline consisting of candidate therapeutics in Cutaneous T-Cell Lymphoma (CTCL), other oncology and adjunct cancer care, anti-infectives, stem cell therapy, and unique prescription products.

8 **Eli Lilly & Company** unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry, and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity, and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

9 **Genentech, Inc.**, for more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.

10 **Genmab US, Inc.** is an international biotechnology company with a core purpose to improve the lives of people with cancer. Founded in 1999, Genmab utilizes its next-generation antibody technologies to create novel therapies. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function-enhanced antibodies, and antibody-drug conjugates. For more info, visit Genmab.com.

11 **GlaxoSmithKline LLC**'s mission and purpose is to deliver potentially transformative medicines and industry-leading programs that provide enduring impact and hope for our patients and their loved ones.

12 **Incyte Corporation** is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware.

13 **Kite Pharma Inc.**, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production, and commercial product manufacturing. For more information on Kite, please visit www.kitepharma.com.

14 At **Merck & Co., Inc.**, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.

15 At **Pfizer Oncology**, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline include game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics, and other immunotherapies. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and thoracic cancers, which include lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients' lives.

16 At **AbbVie/Pharmacyclics | Johnson & Johnson**, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment. Together with our partners – scientists, clinical experts, industry peers, advocates, and patients, we remain focused on delivering transformative advances in treatment. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. AbbVie's oncology portfolio pipeline contains multiple new molecules. For more information, please visit www.abbvie.com/oncology.

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and where solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

17 At **Recordati Rare Diseases, Inc.**, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking, and our actions.

18 **Sobi**, rare strength, is a specialized international biopharmaceutical company, transforming the lives of people with rare and debilitating diseases. Inspired by caring, powered by science, we are dedicated to ensuring every eligible person living with a rare and debilitating disease within our disease areas is given the opportunity to benefit from our approved medicines, delivering innovative solutions from our pipeline, and maintaining our commitment to patients, our employees, and society. For more information, please visit www.sobi.com.

E-Posters

EPCORITAMAB + R-DHAX/C ELICITS DEEP, DURABLE RESPONSES IN TRANSPLANT-ELIGIBLE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING HIGH-RISK DISEASE

P. Abrisqueta,[1] L. Falchi,[2] M. Nijland,[3] S. de Vos,[4] F. Offner,[5] A. Rana,[6] K.G. Archer,[6] Y. Song,[6] K. Osei-Bonsu,[7] Y.H. Karimi,[8] R. Cordoba[9]

[1]Hospital Universitario Vall d'Hebron, Barcelona, Spain; [2]Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; [3]University Medical Center Groningen and University of Groningen, Groningen, Netherlands; [4]Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA, USA; [5]Universitair Ziekenhuis Gent, Ghent, Belgium; [6]Genmab, Plainsboro, NJ, USA; [7]AbbVie, North Chicago, IL, USA; [8]University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; [9]Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

BELLWAVE-011: A PHASE 3 STUDY OF NEMTABRUTINIB VERSUS IBRUTINIB OR ACALABRUTINIB IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Razia Akhtar[1] on behalf of Tamar Tadmor, Tamar Tadmor[2]; Toby A. Eyre[3]; Ohad Benjamini[4]; Arvind Chaudhry[5]; Juan Shen[1]; Siyang Leng[1]; Mohammed Farooqui[1]; David Lavie[6]

[1]Merck & Co., Inc., Rahway, NJ, USA; [2]Bnai Zion Medical Center, Haematology Unit, Haifa, Israel; [3]Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; [4]Sheba Medical Center–Tel HaShomer, Ramat Gan, Israel; [5]Summit Cancer Centers, Spokane, WA, USA; [6]Hadassah Medical Center, Jerusalem, Israel

PRELIMINARY VALIDATION OF A NOVEL PATIENT-REPORTED OUTCOMES (PRO) QUESTIONNAIRE FOR PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: THE CTCL PRO-18

Neha Akkad, MD[1,3], Donna Jeffe, PhD[2], Anastasia Frank[3], Noor Al-Hammadi[4], Marcus Watkins[3], Amy Musiek, MD[5], Neha Mehta-Shah, MD, MSCI[3]

[1]Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA; [2]Department of Medicine, Division of General Medical Sciences, Washington University in St Louis, St. Louis, MO, USA; [3]Department of Medicine, Division of Oncology, Washington University in St. Louis, St. Louis, MO, USA; [4]Department of Health and Clinical Outcomes Research, Saint Louis University, St. Louis, MO, USA; [5]Department of Medicine, Division of Dermatology, Washington University in St. Louis, St. Louis, MO, USA

TRIAL IN PROGRESS: A PHASE 1-2 STUDY OF ZANUBRUTINIB AND TAFASITAMAB (TAFA-ZANU) AS FIRST-LINE TREATMENT OF TRANSPLANT INELIGIBLE MANTLE CELL LYMPHOMA (MCL)

Alvaro Alencar[1], Juan Alderuccio[1], Izidore Lossos[1], Georgios Pongas[1], Juan Carlos Ramos[1], Joseph Rosenblatt[1], Jonathan Schatz[1], Michelle Stanchina[1], Craig Moskowitz[1]

[1]University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

PRIMARY ANALYSIS OF THE PHASE 2 ELM-2 STUDY: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Sabarish Ayyappan,[1] Won Seog Kim,[2] Tae Min Kim,[3] Jan Walewski,[4] Seok-Goo Cho,[5] Isidro Jarque,[6] Elżbieta Iskierka-Jażdżewska,[7] Michelle Poon,[8] Sung Yong Oh,[9] Francesca Lim,[10] Cecilia Carpio,[11] Tran-Der Tan,[12] Antonio Gutierrez,[13] Huilai Zhang,[14] Junning Cao,[15] Mingzhi Zhang,[16] Benoît Tessoulin,[17] Jingjin Li,[18] Melanie Ufkin,[18] Saleem Shariff,[19] Jurriaan Brouwer-Visser,[18] Lei Chi,[18] Aafia Chaudhry,[18] Hesham Mohamed,[18] Srikanth Ambati,[18] H. Miles Prince,[20] on behalf of ELM-2 Investigators

[1]University of Iowa Hospital, Iowa City, IA, USA; [2]Samsung Medical Center, Republic of Korea; [3]Seoul National University Hospital, Seoul, Republic of Korea; [4]Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Panstwowy Instytut Badawczy, Warsaw, Poland; [5]Seoul St. Mary's Hospital, Seoul, Republic of Korea; [6]Hospital Universitario La Fe, Valencia, Spain; [7]Copernicus Memorial Hospital, Łódź, Poland; [8]National University Cancer Institute, Singapore; [9]Dong-A University Hospital, Busan, Republic of Korea; [10]Singapore General Hospital, Singapore; [11]Vall d'Hebron Hospital, Barcelona, Spain; [12]Koo Foundation Sun Yat Sen Cancer Center, Taipei City, Taiwan; [13]Hospital Universitari Son Espases, Palma de Mallorca, Spain; [14]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; [15]Fudan University Shanghai Cancer Center, Shanghai, China; [16]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; [17]Nantes University Hospital, Nantes, France; [18]Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; [19]Regeneron UK Ltd., Uxbridge, UK; [20]Epworth Healthcare and University of Melbourne, Melbourne, Australia

ASSESSMENT OF PHYSICIAN TREATMENT PREFERENCES FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN THE THIRD-LINE SETTING

Wei Gao[1], Savreet Bains Chawla[2], Mu Cheng[1], Raj Desai[1], Jessica Smith[1], Nicole Heaps[2], Alex Mutebi[2], Anthony Wang[3], Jon Ukropec[2]

[1]Analysis Group, Inc., Boston, MA, USA; [2]Genmab US, Inc., Princeton, NJ, USA; [3]AbbVie Inc., North Chicago, IL, USA

RECENT PATTERNS OF CARE WITH BTK INHIBITORS AND DISTRIBUTION OF SOCIAL DETERMINANTS OF HEALTH AMONG PATIENTS WITH CLL/SLL IN THE US COMMUNITY SETTING

David J. Andorsky,[1] Thomas W. Wilson,[2] Kathleen M. Aguilar,[2] Chuck Wentworth,[2] Yunfei Wang,[2] Scott D. Goldfarb,[3] Keri Yang,[3] Erlene K. Seymour,[3] Mark Balk,[3] Gregory A. Maglinte,[3] Ira Zackon[2]

[1]The US Oncology Network/Rocky Mountain Cancer Centers, Boulder, CO, USA; [2]Ontada, Boston, MA, USA; [3]BeiGene USA, Inc, San Mateo, CA, USA

MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL AFTER ≥3 YEARS OF FOLLOW-UP: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY

Sarit Assouline,[1] Nancy L. Bartlett,[2] Matthew Matasar,[3] Stephen J. Schuster,[4] Laurie H. Sehn,[5] John Kuruvilla,[6] Pratyush Giri,[7] Mazyar Shadman,[8] Chan Y. Cheah,[9] Sascha Dietrich,[10] Keith Fay,[11] Matthew Ku,[12] Loretta Nastoupil,[13] Michael C. Wei,[14] Shen Yin,[14] Iris To,[14] Samuel Tracy,[14] Antonia Kwan,[14] Elicia Penuel,[14] L. Elizabeth Budde[15]

[1]Jewish General Hospital, Montreal, QC, Canada; [2]Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA; [3]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [4]Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; [5]BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada; [6]Princess Margaret Cancer Centre, Toronto, ON, Canada; [7]Royal Adelaide Hospital, Adelaide, Australia; [8]Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [9]The University of Western Australia, Perth, Australia; [10]Universitat Heidelberg, Heidelberg, Germany; [11]St Vincent's Hospital and Royal North Shore Hospital, Sydney, Australia; [12]St Vincent's Hospital, University of Melbourne, Melbourne, Australia; [13]MD Anderson Cancer Center, Houston, TX, USA; [14]Genentech, Inc., South San Francisco, CA, USA; [15]City of Hope National Medical Center, Duarte, CA, USA

ORBITAL GERMINAL CENTER DIFFUSE LARGE B-CELL LYMPHOMA

Taras Benzar

The Oncology Institute of Hope And Innovation (TOI), Culver City, California, USA

LENS-SPARING VMAT EBRT FOR THE TREATMENT OF CHOROIDAL LYMPHOMA

C Billena, W Vuong, A Bommireddy, E Murray, A Singh, S, Cherian

Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, US

e-Posters are available on your phone/tablet via the conference app or on your laptop/desktop via the conference portal.

MULTICENTER, RANDOMIZED PHASE II STUDY OF EPCORITAMAB FOR PATIENTS WITH LARGE B-CELL LYMPHOMAS ACHIEVING A PARTIAL RESPONSE AFTER CD19-DIRECTED CAR T-CLL THERAPY

Allison M. Bock, MD[1], Sandeep Raj, MD[2], Sharmila Giri, MS[3], Lori A. Leslie, MD[4], Dilan A. Patel, MD[5], Madiha Iqbal, MBBS, MD[6], Natalie Grover, MD[7], Boyu Hu, MD[1], Miguel-Angel Perales, MD2, Grzegorz S. Nowakowski, MD[8]

[1]Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, US; [2]Memorial Sloan Kettering Cancer Center, New York, NY; [3]ACCRU Statistics and Data Management Center, Mayo Clinic, Rochester, MN, US; [4]Hackensack University Medical Center, Hackensack, NJ; [5]Washington University in Saint Louis, Saint Louis, MO; [6]Mayo Clinic Cancer Center, Jacksonville, FL, US; [7]University of North Carolina School of Medicine, Chapel Hill, NC, US; [8]Mayo Clinic Cancer Center, Rochester, MN, US

TRIAL IN PROGRESS: PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

Elizabeth A Brem,[1] Ruemu Birhiray,[2] Stefano Luminari,[3] Tae Min Kim,[4] Münci Yağci,[5] Timothy Wassenaar,[6] Ashish Risal,[7] Manjusha Namuduri,[7] Jingxian Cai,[7] Bertha Fearon-Chalet,[7] Min Zhu,[7] Sushmita Mukherjee,[7] Jurriaan Brouwer-Visser,[7] Aafia Chaudhry,[7] Hesham Mohamed,[7] Srikanth Ambati,[7] Umberto Vitolo[8]

[1]University of California, Irvine, Orange, CA, USA; [2]Hematology Oncology of Indiana/ American Oncology Network, Indianapolis, IN, USA; [3]Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy; [4]Seoul National University Hospital, Seoul, Republic of Korea; [5]Gazi Universitesi Tip Fakültesi, Ankara, Turkey; [6]ProHealth Care, Waukesha, WI, USA; [7]Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; [8]Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy

CIRCULATING TUMOR DNA ANALYSIS ASSOCIATES WITH PFS WITH ODRONEXTAMAB MONOTHERAPY IN R/R FL AND DLBCL: IDENTIFICATION OF MRD STATUS AND HIGH-RISK SUBGROUPS FROM THE PHASE 2 ELM-2 STUDY

Jurriaan Brouwer-Visser[1], David Tucker[2], Jon E. Arnason[3], Stefano Luminari[4], Tae Min Kim[5], Won Seog Kim[6], Laura Magnano Mayer[7], Dylan Sun[1], Jingxian Cai[1], Kamil Cygan[1], Srikanth Ambati[1], Hesham Mohamed[1], Aafia Chaudhry[1], Vladimir Jankovic[8]

[1]Regeneron Pharmaceuticals, Inc., USA; [2]Royal Cornwall Hospital, United Kingdom; [3]Beth Israel Deaconess Medical Center, USA; [4]Azienda Unità Sanitaria Locale-IRCCS, Italy; [5]Seoul National University Hospital, South Korea; [6]Sungkyunkwan University School of Medicine, Seoul, South Korea; [7]Hospital Clínic de Barcelona, Spain; [8]Regeneron Pharmaceuticals, Inc., USA (at the time of study)

LONG TERM SURVIVAL TRENDS IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE TEXAS CANCER REGISTRY

Ethan A. Burns[1,2], Hala Hassanain[2], Sunil Mathur[3], Darshil Choksi[4], Cesar Gentille[5], Chih-Hang Anthony Tang[1,6], Chih-Chi Andrew Hu[1,6], Hanh Mai[1], Carrie Yuen[1], Shilpan Shah[1], Siddhartha Ganguly[1], Sai Ravi Pingali[1,6]

[1]Houston Methodist Neal Cancer Center, Houston Methodist Hospital. Houston, TX, USA, [2]Department of Academic Medicine, Houston Methodist Hoispital. Houston, TX, USA, [3]Houston Methodist Research Institute, Houston Methodist Hospital. Houston, TX, USA, [4]Dell Medical School, University of Texas. Austin, TX, USA, [5]Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences. Little Rock, AR, USA, [6]Center for Translational Research in Hematologic Malignancies, Houston Methodist Research Institute. Houston, TX

Congratulations

2024 PPLC Abstract Travel Stipend Recipients

Neha Akkad, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Allison Bock, MD
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah

Jessica Davis, DNP
Sansum Clinic
Santa Barbara, CA

Eduardo Edelman Saul, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Joseph Anthony El Ghoubaira, MD
UPMC Hillman Cancer Center/University of Pittsburgh
Pittsburgh, PA

Hyunju Hong, MSN, APN
Division of Hematology/National Cancer Center
Republic of Korea

Dylan Jochum
University of Nebraska Medical Center
Omaha, NE

Amina Namrouti, BS
Herbert Wertheim College of Medicine
Florida International University
Miami, FL

Izel Okcu, MD
Mayo Clinic
Rochester, MN

Stacy Pak, PharmD, BCOP
City of Hope
Duarte, CA

Sunandini Sharma, PhD
University of Nebraska Medical Center
Omaha, NE



E-Posters

CUTANEOUS MANTLE CELL LYMPHOMA: AN MD ANDERSON CANCER CENTER EXPERIENCE

W. Chen, M. Badillo, C. Gaulin, J. Zhang, S. Wu, P. Jain, C. Ok, F. Yan, O. Oriabure, B. Dabaja, J. Gunther, P. Fang, C. Pinnix, M. Wang

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PRIMARY ANALYSIS OF THE PHASE 2 ELM-2 STUDY: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Geoffrey Chong,[1] Michal Taszner,[2] Silvana Novelli,[3] Seok-Goo Cho,[4] Jose C. Villasboas,[5] Ana Jiménez Ubieto,[6] Benoît Tessoulin,[7] Michelle Poon,[8] David Tucker,[9] Jan Walewski,[10] Yuqin Song,[11] Emmanuel Bachy,[12] Stéphanie Guidez,[13] Aranzazu Alonso,[14] Deepa Jagadeesh,[15] Stefano Luminari,[16] Laura Magnano Mayer,[17] Elżbieta Iskierka-Jażdżewska,[18] Monica Tani,[19] Jingxian Cai,[20] Amulya Uppala,[20] Saleem Shariff,[21] Jurriaan Brouwer- Visser,[20] Aafia Chaudhry,[20] Hesham Mohamed,[20] Srikanth Ambati,[20] Tae Min Kim[22] on behalf of ELM-2 Investigators

[1]Olivia Newton-John Cancer Centre, Australia; [2]Medical University of Gdańsk, Poland; [3]Hospital de la Santa Creu i Sant Pau, Spain; [4]Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea; [5]Mayo Clinic, USA; [6]Hospital Universitario 12 de Octubre, Spain; [7]Nantes University Hospital, France; [8]National University Cancer Institute, Singapore; [9]Royal Cornwall Hospital, UK; [10]Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Poland; [11]Peking University Cancer Hospital and Institute, China; [12]Hospices Civils de Lyon and Université Claude Bernard Lyon 1, France; [13]Centre Hospitalier Universitaire, France; [14]Hospital Universitario Quiron Salud Madrid, Spain; [15]Cleveland Clinic, USA; [16]Azienda Unità Sanitaria Locale-IRCCS, Italy; [17]Hospital Clínic de Barcelona, Spain; [18]Copernicus Memorial Hospital, Poland; [19]Santa Maria delle Croci Hospital, Italy; [20]Regeneron Pharmaceuticals, Inc., USA; [21]Regeneron UK Ltd., UK; [22]Seoul National University Hospital, Republic of Korea

EPCORITAMAB + GEMOX INDUCES DEEP, DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM THE EPCORE NHL-2 TRIAL

R. Cordoba,[1] J. Jørgensen,[2] D. Belada,[3] R. Costello,[4] M. Trněný,[5] U. Vitolo,[6] D.J. Lewis,[7] Y.H. Karimi,[8] A. Sureda,[9] M. André,[10] B.E. Wahlin,[11] P.J. Lugtenburg,[12] T. Jiang,[13] A. Abbas,[14] Y. Song,[14] M. Risum,[15] J.D. Brody[16]

[1]Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain; [2]Aarhus University Hospital, Aarhus, Denmark; [3]4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; [4]Assistance Publique – Hôpitaux de Marseille (AP-HM), Marseille, France; [5]First Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; [6]Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy; [7]University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK; [8]University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; [9]Clinical Hematology Department, Institut Català d'Oncologia – L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; [10]CHU UCL Namur, Yvoir, Belgium; [11]Karolinska Institutet, Stockholm, Sweden; [12]On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands; [13]AbbVie, North Chicago, IL, USA; [14]Genmab, Plainsboro, NJ, USA; [15]Genmab, Copenhagen, Denmark; [16]Icahn School of Medicine at Mount Sinai, New York, NY, USA

EFFICACY AND SAFETY OF E7777 (IMPROVED PURITY DENILEUKIN DIFTITOX [ONTAK]) IN PATIENTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA: RESULTS FROM PIVOTAL STUDY 302

Francine Foss[1], MD, Youn H Kim[2], MD, Miles Prince[3], MD, FRACP, FRCPA, Christiane Querfeld[4], MD, PhD, Costas K Yannakou[5] MBBS, FRACP, FRCPA, PhD, Chean Eng Ooi[6], PhD, Dongyuan Xing[6], PhD, Nicholas Sauter[6], MD, Preeti Singh[7], MD, Myron Czuczman[7], MD, Madeleine Duvic[8], MD

[1]Yale Cancer Center, Yale Medical Group, New Haven, CT; [2]Departments of Dermatology & Medicine, Stanford Cancer Center, Stanford, CA; [3]Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; [4]Department of Dermatology, City of Hope Comprehensive Cancer Center, Duarte, CA; [5]Epworth HealthCare, Melbourne, Australia; [6]Eisai Inc., Nutley, NJ; [7]Citius Pharmaceuticals, Cranford, NJ; [8]Department of Dermatology, The University of Texas - MD Anderson Cancer Center, Houston, TX

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VS MOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES

Alexey Danilov,[1] Swetha Kambhampati,[1] Kim Linton,[2] Karen Cumings,[3] Viktor Chirikov,[3] Alex Mutebi,[4] Savreet Bains Chawla,[4] Fernando Rivas Navarro,[5] Anthony Wang,[6] Zhijie Ding,[4] Abualbishr Alshreef,[6] Elena Favaro,[5] Daniela Hoehn,[4] Anna Sureda[7]

[1]City of Hope, Duarte, CA, USA; [2]The Christie NHS Foundation Trust, Manchester Cancer Research Center, and Division of Cancer Sciences, University of Manchester, Manchester, UK; [3]OPEN Health, Hingham, MA, USA; [4]Genmab US Inc., Plainsboro, NJ, USA; [5]Genmab, Copenhagen, Denmark; [6]AbbVie, Inc., North Chicago, IL, USA; [7]Clinical Hematology Department, Institut Català d'Oncologia – L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain

IMPROVING ADVANCE CARE PLANNING OUTCOMES

Jessica Davis, DNP

Sansum Clinic, Santa Barbara, CA

TRANSCRIPTIONAL REGULATION OF CELL CYCLE PROGRESSION IN B CELL LYMPHOMA

S. Dovat[1], D. Bogush[1], A. Sharma[1], and D. Desai[1]

[1]Penn State University College of Medicine, Hershey, PA, USA

TRANSCEND FL: PHASE 2 STUDY PRIMARY ANALYSIS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) THERAPY IN PATIENTS (PT) WITH HIGH-RISK R/R FL

F Morschhauser,[1] S Dahiya,[2] ML Palomba,[3] AM Garcia-Sancho,[4] JLR Ortega,[5] J Kuruvilla,[6] U Jäger,[7] G Cartron,[8] K Izutsu,[9] M Dreyling,[10] B Kahl,[11] H Ghesquieres,[12] K Ardeshna,[13] H Goto,[14] AM Barbui,[15] JS Abramson,[16] P Borchmann,[17] I Fleury,[18] S Mielke,[19] A Skarbnik,[20] S de Vos,[21] Manali Kamdar,[22] R Karmali,[23] A Viardot,[24] T Farazi,[25] M Vedal,[25] R Nishii,[25] A Avilion,[25] J Papuga,[25] LJ Nastoupil[26]

[1]Centre Hospitalier Universitaire de Lille, Lille, France; [2]Stanford University School of Medicine, Stanford, CA, USA; [3]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [4]Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain; [5]Hospital Universitario Virgen del Rocío, IBIS/CSIC, Universidad de Sevilla, Seville, Spain; [6]Princess Margaret Cancer Centre, Toronto, ON, Canada; [7]Medical University of Vienna, Vienna, Austria; [8]Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France; [9]National Cancer Center Hospital, Tokyo, Japan, [10]Medizinische Klinik III, Klinikum der Universität, LMU München, München, Germany; [11]Washington University School of Medicine in St. Louis, St. Louis, MO, USA; [12]Hôpital Lyon Sud, Lyon, France; [13]University College London Hospitals NHS Foundation Trust-University College Hospital, London, UK; [14]Hokkaido University Hospital, Sapporo, Japan; [15]Azienda Socio Sanitaria Terriroriale Papa Giovanni XXIII, Bergamo, Italy; [16]Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; [17]Universität zu Köln, Köln, Germany; [18]Hôpital Maisonneuve – Rosemont, Montreal, QC, Canada; [19]Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; [20]Novant Health Cancer Institute, Charlotte, NC, USA; [21]UCLA Santa Monica Medical Centre, Santa Monica, CA, USA; [22]University of Colorado Cancer Center, Aurora, CO, USA; [23]Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA; [24]University Hospital, Ulm, Germany; [25]Bristol Myers Squibb, Princeton, NJ, USA; [26]The University of Texas MD Anderson Cancer Center, Houston, TX, USA

e-Posters are available on your phone/tablet via the conference app or on your laptop/desktop via the conference portal.

DREAMM-7 UPDATE: SUBGROUP ANALYSES FROM A PHASE 3 TRIAL OF BELANTAMAB MAFODOTIN (BELAMAF) + BORTEZOMIB AND DEXAMETHASONE (BVD) VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM)

María Victoria Mateos Manteca[1]; Pawel Robak[2]; Marek Hus[3]; ChengCheng Fu[4]; Vera Zherebtsova[5]; Christopher Ward[6]; P. Joy Ho[7]; Ana Carolina de Almeida Ribas[8]; Roman Hajek[9]; Kihyun Kim[10]; Meletios Dimopoulos[11]; Claudio Cerchione[12]; Nick Pirooz[13]; Astrid McKeown[14]; Benga Kazeem[14]; Hena Baig[15]; Lydia Eccersley[16]; Sumita Roy-Ghanta[13]; Joanna Opalinska[13]; Vania Hungria[17]

[1]Hospital Universitario de Salamanca, Salamanca, Spain; [2]Medical University of Lodz, Lodz, Poland; [3]Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland; [4]The First Affiliated Hospital of Soochow University, Suzhou, China; [5]Gorodskaya Klinicheskaya Bol'nitsa Im. S.p. Botkina, Moscow, Russia; [6]Royal North Shore Hospital, Sydney, Australia; [7]Royal Prince Alfred Hospital, Camperdown, NSW, Australia; [8]Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis, Brazil; [9]University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic; [10]Sungkyunkwan University, Samsung Medical Center, Seoul, Korea; [11]National and Kapodistrian University of Athens, Athens, Greece; [12]Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy; [13]GSK, Upper Providence, PA USA; [14]GSK, Stevenage, UK; [15]GSK, Mississauga, ON, Canada; [16]GSK, London, UK; [17]Clinica São Germano, São Paulo, Brazil.

STAGING FDG-AVIDITY IN EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) BY DISEASE LOCATION

E. Edelman Saul[1], J.P. Alderuccio[2], M. Stanchina[2], M. Polar[2], R. Hennemann Sassi[2], W. Zhao[2], C.H. Moskowitz[2], I. Reis[2], R. Kuker[2], I. Lossos[2]

[1]Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, [2]Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida, USA

HYPERAMMONEMIC ENCEPHALOPATHY IN MULTIPLE MYELOMA: SYSTEMATIC REVIEW AND CASE SERIES

Joseph Anthony El Ghoubaira MD[1], Aseel Alsouqi MD[1], Elia Abou Chawareb MD[2], Rita Farah MPH, PharmD, PhD[3], Rafic J. Farah MD[1]

[1]UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; [2]Department of Urology, University of California, Irvine, California; [3]Division of Medical Toxicology, Department of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, Virginia

NASOPHARYNGEAL MALT LYMPHOMA: A CASE REPORT

Eiman Elmileik and Carlos Galvez

University of Illinois at Chicago, Chicago, IL

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) IN PREVIOUSLY UNTREATED (1L) FOLLICULAR LYMPHOMA (FL) AND EPCORITAMAB MAINTENANCE THERAPY IN FL: NOVEL RESULTS FROM EPCORE NHL-2 ARMS 6 AND 7

L. Falchi,[1] J.S.P. Vermaat,[2] G. Musuraca,[3] M. Nijland,[4] J.H. Christensen,[5] F. Offner,[6] L.A. Leslie,[7] J.D. Brody,[8], D. Hoehn,[9] J. Marek,[9] L. Wang,[9] J. Mei,[10] D. Belada,[11] P. Abrisqueta[12]

[1]Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; [2]Leiden University Medical Center, Leiden, Netherlands; [3]Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy; [4]University Medical Center Groningen and University of Groningen, Groningen, Netherlands; [5]Odense University Hospital, Odense, Denmark; [6]Universitair Ziekenhuis Gent, Ghent, Belgium; [7]John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA; [8]Icahn School of Medicine at Mount Sinai, New York, NY, USA; [9]Genmab, Plainsboro, NJ, USA; [10]AbbVie, North Chicago, IL, USA; [11]4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; [12]Hospital Universitario Vall d'Hebron, Barcelona, Spain

USE OF BISPECIFIC T-CELL ENGAGING ANTIBODIES (BSABS) IN COMMUNITY PRACTICES: MULTIDISCIPLINARY PERSPECTIVES ON DEVELOPING LOGISTICS AND WORKFLOW FOR CYTOKINE RELEASE SYNDROME (CRS) MANAGEMENT

William Donnellan,[1] Shih-Wen Lin,[2] Jonathan Abbas,[1] Jesus G. Berdeja,[1] Lourenia Cassoli,[2] Jason C. Chandler,[3] Brannon Flores,[2] Sara Hall,[4] Arliene Mangalindan,[2] Anthony Masaquel,[2] Sharifa Patterson,[1] Eileen Peng,[5] Ashley Todd,[1] Chelsea Traughber,[1] Lisa Raff[6]

[1]Tennessee Oncology, Nashville, TN, USA; [2]Genentech, Inc., South San Francisco, CA, USA; [3]West Cancer Center, Germantown, TN, USA; [4]University Cancer & Blood Center, Athens, GA, USA; [5]Astera Cancer Care, Edison, NJ, USA; [6]OneOncology, Chicago, IL, USA

HEPATOSPLENIC T-CELL LYMPHOMA, αβ TYPE, PRESENTING IN AN ELDERLY PATIENT STATUS POST INDOLENT B-CELL LYMPHOMA TREATMENT

Rodolfo Garza-Morales[1], Allison Rosenthal[1], Jiehao Zhou[2]

[1]Department of Medicine, Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; [2]Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Phoenix, AZ, USA.

THE ADVANCED PRACTICE PROVIDERS IDENTIFICATION OF GRADE 3 TOXCITIES ASSOCIATED WITH BRUTON KINASE INHIBITORS IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

M.D. Guerrero DNP,NP-C,AOCNP

MD Anderson Cancer Center, Houston, TX USA

TRIAL IN PROGRESS: PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2)

Colin Hardin,[1] Carl Gray,[2] Silvana Novelli,[3] Tuba Hacibekiroğlu,[4] Münci Yağci,[5] Ruemu Birhiray,[6] Ashish Risal,[7] Manjusha Namuduri,[7] Jingxian Cai,[7] Melanie Ufkin,[7] Min Zhu,[7] Sushmita Mukherjee,[7] Jurriaan Brouwer-Visser,[7] Aafia Chaudhry,[7] Hesham Mohamed,[7] Srikanth Ambati,[7] Elżbieta Iskierka-Jażdżewska[8]

[1]The Cancer & Hematology Centers, Grand Rapids, MI, USA; [2]Community Cancer Trials of Utah, Ogden, UT, USA; [3]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; [4]Department of Hematology, Sakarya University, Sakarya, Turkey; [5]Gazi Universitesi Tip Fakültesi, Ankara, Turkey; [6]Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN, USA; [7]Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; [8]Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland

CNS TUBERCULOSIS IN A PATIENT WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: A CASE STUDY

Zoey Harris, MD[1], Connor Yost, MD[1], Yael Kusne, MD[1], Allison Rosenthal, DO[1]

[1]Division of Hematology and Medical Oncology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA

E-Posters

LONG-TERM SECONDARY CAUSE-SPECIFIC MORTALITY IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE TEXAS CANCER REGISTRY

Hala Hassanain[1,2], Ethan A. Burns[1,3], Sunil Mathur[3], Darshil Choksi[4], Cesar Gentille[5], Chih-Hang Anthony Tang[3,6], Chih-Chi Andrew Hu[3,6], Hanh Mai[3], Carrie Yuen[3], Shilpan Shah[3], Siddhartha Ganguly[3], Sai Ravi Pingali[3]

[1]Department of Academic Medicine, Houston Methodist Hoispital. Houston, TX, USA; [2]Burroughs Wellcome Fund Fellow, Texas A&M Academy of Physician Scientists, Houston, TX; [3]Houston Methodist Neal Cancer Center, Houston Methodist Hospital. Houston, TX, USA; [4]Dell Medical School, University of Texas. Austin, TX, USA; [5]Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences. Little Rock, AR, USA; [6]Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute. Houston, TX

DECIPHERING THE CLINICAL BENEFIT OF POLA-R-CHP VERSUS R-CHOP IN DIFFERENT GENETIC SUBTYPES BEYOND CELL OF ORIGIN IN THE POLARIX STUDY

Franck Morschhauser,[1] Wilfred Leung,[2] Vibha Raghavan,[3] Georg Lenz,[4] Fabrice Jardin,[5] Alex F. Herrera,[6] Laurie H. Sehn,[7] Jeff P. Sharman,[8] Christopher R. Flowers,[9] Jonathan W. Friedberg,[10] Marek Trněný,[11] Hervé Tilly,[5] Charles Herbaux,[12] Samuel Tracy,[2] Christopher R. Bolen,[2] Will Harris,[2] Jamie H. Hirata,[2] Calvin Lee,[2] Yanwen Jiang,[2] Connie Lee Batlevi,[2] Gilles Salles[13]

[1]University of Lille, Lille, France; [2]Genentech, Inc., South San Francisco, CA, USA; [3]Hoffmann-La Roche Ltd, Mississauga, ON, Canada; [4]University Hospital Münster, Münster, Germany; [5]Centre Henri-Becquerel and University of Rouen, Rouen, France; [6]City of Hope, Duarte, CA, USA; [7]BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada; [8]Willamette Valley Cancer Institute and Research Center, Florence, OR, USA; [9]M.D. Anderson Cancer Center, Houston, TX, USA; [10]University of Rochester, Rochester, NY, USA; [11]Charles University General Hospital, Prague, Czech Republic; [12]University of Montpellier, Montpellier, France; [13]Memorial Sloan Kettering Cancer Center, New York, NY, USA

THE IMPACT OF COMMUNICATION WITH HEALTHCARE PROVIDERS ON DAILY LIVING ADJUSTMENT IN PATIENTS WITH LYMPHOMA

Hyunju Hong, Ehwa Yun, Bobae Jeong, Ahyeong Jo, Yeongme Kim, Yunseon Choe, Kwangmi Lee

Division of Hematology, National Cancer Center, 323 Ilsan-ro, Goyang-si, Gyeonggi-do, 10408, Republic of Korea

A GLOBAL PHASE 2 TRIAL OF NANATINOSTAT IN COMBINATION WITH VALGANCICLOVIR IN PATIENTS WITH EBV- POSITIVE (EBV+) RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMAS (NAVAL-1)

Swaminathan Iyer, MD[1], Ranjit Nair, MD[2], Hung Chang, MD[3], Irl Brian Greenwell, MD[4], Hui-Hua Hsiao, MD, PhD[5], Luigi Zinzani, MD[6], Kiran Vangipuram, PharmD[7], Donald Strickland, MD[7], Eva González-Barca, MD[8]

[1]Professor of Medicine, Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX USA; [2]Clinical Medical Director, Department of Lymphoma of Myeloma, MD Anderson Cancer Center, Houston, TX USA; [3]Division of Hematology, CGMH-Linko, School of Medicine, Chang Gung University, Taoyuan, Taiwan; [4]Associate Professor, Department of Medicine, Medical University of South Carolina, Charleston, SC USA; [5]Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan; [6]Professor, Department of Medicine and Surgical Services, University of Bologna, Bologna IT; [7]Viracta Therapeutics Inc, Cardiff CA USA; [8]Department of Hematology, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain

PATIENTS WITH R/R LARGE B-CELL LYMPHOMA (LBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL) NONCONFORMING PRODUCT (NCP) UNDER THE EXPANDED ACCESS PROTOCOL (EAP)

BG Till,[1] C Jacobson,[2] ML Palomba,[3] JS Abramson,[4] J Arnason,[5] FL Locke,[6] P Caimi,[7] N Grover,[8] R Karmali,[9] HC Suh,[10] SJ Schuster,[11] M Gharibo,[12] C Balint,[12] T Rakhmawati,[13] V Jude,[12] LJ Nastoupil[14]

[1]Fred Hutchinson Cancer Center, Seattle, WA, USA; [2]Dana-Farber Cancer Institute, Boston, MA, USA; [3]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [4]Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; [5]Beth Israel Deaconess Medical Center, Boston, MA, USA; [6]H Lee Moffitt Cancer Center, Tampa, FL, USA; [7]CCF Taussig Cancer Center, Cleveland, OH, USA; [8]Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA; [9]Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA; [10]John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; [11]Lymphoma Program, Abramson Cancer Center, Philadelphia, PA, USA; [12]Bristol Myers Squibb, Princeton, NJ, USA; [13]Syneos Health, Morrisville, NC, USA; [14]The University of Texas MD Anderson Cancer Center, Houston, TX, USA

CCR4 MUTATIONS DYSREGULATE T-HELPER DIFFERENTIATION AND PROMOTE LYMPHOMAGENESIS

Dylan T Jochum[1], Suchita Vishwakarma[2], Alyssa Bouska[1], Waseem G Lone[1], Ab Rauf Shah[5], Abdul Rouf Mir[1], Sunandini Sharma[1], Mehnaz Tabassum[1], Zaina Nasser[3], Amarnath Natarajan[4], and Javeed Iqbal[1]

[1]Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE [2]Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE; [3]College of Arts and Sciences, University of Nebraska, Lincoln, NE; [4]Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE

THE MULTICOLOR FLOW CYTOMETRY FOR PRIMARY VITREORETINAL LYMPHOMA DIAGNOSIS: A SINGLE CENTER EXPERIENCE

Jakrawadee Julamanee[1], Kajornkiat Maneechai[1], Panarat Noiperm[1], Wantanee Sittivarakul[2], Wantanee Dangboon Tsutsumi[2]

[1]Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand; [2]Division of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH EPCORITAMAB

Wojciech Jurczak,[1] Umberto Vitolo,[2] Kim M. Linton,[3] Anupama Kalsekar,[4] Anindit Chhibber,[4] Elena Favaro,[5] Alex Mutebi,[4] Savreet Bains Chawla,[4] Anthony Wang,[6] Diana Gernhardt,[4] Julie Blaedel,[4] Pieternella Lugtenburg[7]

[1]MSC National Research Institute of Oncology, Kraków, Poland; [2]Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy; [3]The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK; [4]Genmab US Inc., Plainsboro, NJ, USA; [5]Genmab, Copenhagen, Denmark; [6]AbbVie Inc., North Chicago, IL, USA; [7]On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, The Netherlands

e-Posters are available on your phone/tablet via the conference app or on your laptop/desktop via the conference portal.

SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER'S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL

A.P. Kater,[1] A. Janssens,[2] H. Eradat,[3] F. Offner,[4] J.D. Sandoval-Sus,[5] M. Shadman,[6] C.B. Poulsen,[7] J.H. Christensen,[8] M.C. Thompson,[9] M. Rios,[10] A. Kuznetsova,[11] T. Oki,[12] R. Valentin,[11] M. Bellido,[13] B. Eichhorst[14]

[1]Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands; [2]University Hospitals Leuven, Leuven, Belgium; [3]David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; [4]Universitair Ziekenhuis Gent, Ghent, Belgium; [5]Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL, USA; [6]Fred Hutchinson Cancer Center, Seattle, WA, USA; [7]Zealand University Hospital, Roskilde, Denmark; [8]Odense University Hospital, Odense, Denmark; [9]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [10]Genmab, Plainsboro, NJ, USA; [11]Genmab, Copenhagen, Denmark; [12]AbbVie, North Chicago, IL, USA; [13]University Medical Center Groningen and University of Groningen, Groningen, Netherlands; [14]University Hospital Cologne, Cologne, Germany

RETREATMENT WITH NKX019 (CD19-TARGETED CAR NK CELL THERAPY) IS FEASIBLE, SAFE, AND EFFECTIVE WITH IN SUBJECTS WITH NHL

Brian Hill[1], Mark Dowling[2], Christian Bryant[3], Vinay Vanguru[3], Nada Hamad[4], Michael Tees[5], Phung Gip[6], Sandeep Hora[6], Nishi Kothari[6], David Shook[6], and Michael Dickinson[2]

[1]Cleveland Clinic, Cleveland, United States of America; [2] Peter MacCallum Cancer Centre, Melbourne, Australia; [3]Royal Prince Alfred Hospital, Sydney, Australia; [4]St. Vincent Hospital, Sydney, Australia; [5]Colorado Blood Cancer Institute, Denver, United States of America; [6]Nkarta, Inc., South San Francisco, United States of America

REAL-WORLD TREATMENT PATTERNS AND PATIENT OUTCOMES IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA IN THE US

Fjoralba Kristo, MD, MPH[1]; Melissa Lingohr-Smith, PhD[2]; Jay Lin, PhD, MBA[2]; Ajibade Ashaye, MD, MBA, MPH, MSc[1]

[1]Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421 USA; [2]Novosys Health, Green Brook, NJ, USA

SAFETY AND EFFICACY OF BRETUXIMAB VEDOTIN WITH PROPHYLACTIC G-CSF IN CLASSICAL HODGKIN LYMPHOMA (SGN35-027, PART A)

Hun Ju Lee,[1] Ian Flinn,[2] Leland Metheny,[3] Judah Friedman,[4] Joseph Mace,[5] Paul Gonzales,[6] Ameet Patel,[7] Mihir Raval,[8] Asad Dean,[9] Griffith Davis,[10] Wenchuan Guo,[10] Michelle Fanale,[10] Chris Yasenchak[11]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX, USA; [2]Tennessee Oncology, Nashville, TN, USA; [3]Case Western Reserve University, Cleveland, OH, USA; [4]Florida Cancer Specialists, Palm Beach Gardens, FL, USA; [5]Florida Cancer Specialists, Saint Petersburg, FL, USA; [6]Brooke Army Medical Center, San Antonio, TX, USA; [7]Oncology Hematology Care, Cincinnati, OH, USA; [8]New York Oncology Hematology PC, Albany, NY, USA; [9]Texas Oncology, Fort Worth, TX, USA; [10]Pfizer Inc, Bothell, WA, USA; [11]Willamette Valley Cancer Institute, Eugene, OR, USA

COMPARISON OF CLONOSEQ AND MULTIPARAMETER FLOW CYTOMETRIC ANALYSIS OF MINIMAL RESIDUAL DISEASES IN MYELOMA

FNU Sameeta, Pei Lin

Department of Hematopathology, University of Texas-MD Anderson Cancer Center, Houston, Texas, 77030

CAR T ADMINISTERED IN THE OUTPATIENT SETTING FOR DLBCL: PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE RESOURCE USE

Anik R. Patel[1], Ken Hasegawa[1], Shivani Pandya[2], Liucheng Shi[2], Constance Lau[1], Frederick L. Locke[3]

[1]Kite, A Gilead Company, Santa Monica, CA; [2]IQVIA, Falls Church, VA; [3]H. Lee Moffitt Cancer Center and Research Institute, Tampa FL

COOPERATIVE ROLE OF TET2 AND IDH2 MUTATIONS GENERATES T-CELL LYMPHOMA WITH TFH-CELL IMMUNOPHENOTYPE AND DIFFERENTIATION BLOCK IN TH1 PROGRAM

Waseem Lone[1], Alyssa Bouska[1], Tayla B. Heavican-Foral[2], Tyler Herek[1], Abdul Rauf Shah[1], Abdul Rouf Mir[1], Dylan Jochum[1], Catalina Amador[3], Andrew Feldman[4], Wing C. Chan[5], and Javeed Iqbal[1]

[1]Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; [2]Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; [3] Department of Pathology, University of Miami, Miami, FL; [4]Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN; [5]Department of Pathology, City of Hope National Medical Center, Duarte, CA

REAL-WORLD BRUTON TYROSINE KINASE INHIBITOR TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA IN US COMMUNITY ONCOLOGY PRACTICES

Jing-Zhou Hou[1], Simon Blanc[2], Gregory A. Maglinte[3], Anupama Vasudevan[2], Anna Rui[2], Mike Gart[2], Hoa Pham[3], Lindsay Aton[2], Brandon Wang5, Rushir Choksi[1]

[1]UPMC, Pittsburgh, Pennsylvania, United States of America, [2]Integra Connect, West Palm Beach, Florida, United States of America, [3]BeiGene USA, Inc., San Mateo, CA, United States of America

REAL-WORLD COST OF DISEASE PROGRESSION (PD) AFTER FRONTLINE (1L) R- CHOP IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN ANALYSIS OF A LARGE US CLAIMS DATABASE

Anthony Masaquel,[1] John Burke,[2] Rongrong Wang,[1] Farah Hossain,[1] Jia Li,[1] Matthew Matasar[3]

[1]Genentech Inc., South San Francisco, CA, USA, [2]Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USA, [3]Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

TRIAL IN PROGRESS: PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP VERSUS RITUXIMAB PLUS CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL; OLYMPIA-3)

Matthew Matasar,[1,2] Burhan Turgut,[3] Benoît Tessoulin,[4] Stéphanie Guidez,[5] Münci Yağci,[6] Nazia Iqbal,[7] Manjusha Namuduri,[7] Alice Cao,[7] Nickolas Sophos,[7] Katherine Kargus,[7] Min Zhu,[7] Siobhán Nolan,[7] Jurriaan Brouwer-Visser,[7] Aafia Chaudhry,[7] Srikanth Ambati,[7] Hesham Mohamed,[7] David Tucker[8]

[1]Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, USA; [2]Rutgers Robert Wood Johnson Medical School, USA; [3]Namık Kemal Üniversitesi, Turkey; [4]Nantes University Hospital, France; [5]Centre Hospitalier Universitaire, France; [6]Gazi Universitesi Tip Fakültesi, Ankara, Turkey; [7]Regeneron Pharmaceuticals, Inc., USA; [8]Royal Cornwall Hospital, UK

E-Posters

PATIENT-REPORTED OUTCOMES (PROS) FROM THE DREAMM-7 RANDOMIZED PHASE 3 STUDY COMPARING BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE (BVD) VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Vania Hungria[1]; Pawel Robak[2]; Marek Hus[3]; ChengCheng Fu[4]; Vera Zherebtsova[5]; Christopher Ward[6]; Ana Carolina de Almeida Ribas[7]; P. Joy Ho[8]; Roman Hajek[9]; Claudio Cerchione[10]; Nick Pirooz[11]; Astrid McKeown[12]; Hena Baig[13]; Lydia Eccersley[14]; Farrah Pompilus[15]; Chee Paul Lin[11]; Sumita Roy-Ghanta[11]; Joanna Opalinska[11]; María Victoria Mateos Manteca[16]

[1]Clinica São Germano, São Paulo, Brazil; [2]Medical University of Lodz, Lodz, Poland; [3]Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland; [4]The First Affiliated Hospital of Soochow University, Suzhou, China; [5]Gorodskaya Klinicheskaya Bol'nitsa Im. S.p. Botkina, Moscow, Russia; [6]Royal North Shore Hospital, Sydney, Australia; [7]Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis, Brazil; [8]Royal Prince Alfred Hospital, Camperdown, NSW, Australia; [9]University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic; [10]Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy; [11]GSK, Upper Providence, PA USA; [12]GSK, Stevenage, UK; [13]GSK, Mississauga, ON, Canada; [14]GSK, London, UK; [15]GSK, Boston, MA USA; [16]Hospital Universitario de Salamanca, Salamanca, Spain.

MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN: SUBGROUP ANALYSES IN PATIENTS (PTS) WITH PRIMARY REFRACTORY OR EARLY RELAPSED LARGE B-CELL LYMPHOMA (LBCL)

Sarit Assouline,[1] Lihua Elizabeth Budde,[2] Julio C. Chavez,[3] Catherine S. Diefenbach,[4] Kathleen Anne Dorritie,[5] Nilanjan Ghosh,[6] Adam J. Olszewski,[7] Izidore S. Lossos,[8] Amitkumar Mehta,[9] Dipenkumar Modi,[10] Seema Naik,[11] Stephen Douglas Smith,[12] Sneha Makadia,[13] Song Pham,[14] Hao Wu,[13] Connie Lee Batlevi,[13] Iris To,[13] Michael C. Wei,[13] Manali Kamdar[15]

[1]Jewish General Hospital, McGill University, Montreal, Quebec, Canada; [2]City of Hope National Medical Center, Duarte, CA; [3]Moffitt Cancer Center, Tampa, FL; [4]Perlmutter Cancer Center at NYU Langone Health, New York, NY; [5]UPMC Hillman Cancer Center, University of Pittsburgh, PA; [6]Levine Cancer Institute/Atrium Health, Charlotte, NC; [7]Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI; [8]University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL; [9]University of Alabama at Birmingham, Birmingham, AL; [10]Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI; [11]Penn State University College of Medicine, Hershey, PA; [12]Fred Hutchinson Cancer Center, University of Washington, Seattle, WA; [13]Genentech, Inc., South San Francisco, CA; [14]F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; [15]University of Colorado, Aurora, CO.

TRANSDIFFERENTIATION WITH GENOTYPIC EVIDENCE OF A CLONAL RELATIONSHIP BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND HISTIOCYTIC SARCOMA: A CASE REPORT

Karmila C. Murphy MSN, APRN, FNP-C, Anath C. Lionel, Preetesh Jain, L. Jeffrey Medeiros, Dai Chihara

Department of Lymphoma and Myeloma, Department of Pathology, MD Anderson Cancer Center. 1515 Holcombe Blvd Unit 429, Houston TX 77030.

LOGISTICAL CHALLENGES ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR T) IN NON-HODGKIN LYMPHOMA (NHL): A SURVEY OF HEALTHCARE PROFESSIONALS

Anna Sureda,[1] Shiraz El Adam,[2] Shibing Yang,[3] Evelyn Griffin,[2] Jenny Baker,[2] Karissa Johnston,[2] Fernando Rivas Navarro,[4] Sarah Alhasani,[3] Anindit Chhibber,[3] Anthony Wang,[5] Alex Mutebi[3]

[1]Institut Català d'Oncologia – L'Hospitalet, IDIBELL, Universitat de Barcelona, Clinical Hematology Department, Barcelona, Spain; [2]Broadstreet HEOR, Vancouver, Canada; [3]Genmab US Inc., Plainsboro, NJ, USA; [4]Genmab, Copenhagen, Denmark; [5]AbbVie Inc., North Chicago, IL, USA

EARLIER TIME POINT ASSESSMENT OF METHOTREXATE CONCENTRATIONS PREDICTIVE OF NEPHROTOXICITY IN PATIENTS RECEIVING HIGH DOSE METHOTREXATE FOR DIFFUSE LARGE B CELL LYMPHOMA

Farsha Rizwan, MD*[1], Rachel Thomas, MD*[1], Karen Ruth, MS[3], Charan Loya, MS[3], Nadia Khan, MD[2], Zachary Frosch, MD, MSHP[3], Marcus Messmer, MD[3], Lynn Y. Wang, MD, PhD[3], Shazia Nakhoda, MD[3]

*[1]Temple University Hospital System; [2]Swedish Health Services; [3]Fox Chase Cancer Center/Temple University Hospital System (*co-first authors)*

COMPARATIVE ANALYSIS OF LUMBAR PUNCTURE UTILITY IN DIAGNOSIS OF PRIMARY VERSUS SECONDARY CNS LYMPHOMA: A RETROSPECTIVE STUDY

Amina Namrouti[1], Mainak Bardhan[2], Tiba Al Sagheer[3], Yuliya Linhares[3],Muni Rubens[4] ,Yazmin Odia[2], Manmeet S Ahluwalia[2], Zhijian Chen[2]

[1]Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA; [2]Neuro-Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL USA; [3]Hematologic Malignancies & Stem Cell Transplant, Miami Cancer Institute, Baptist Health South Florida, FL, USA; [4]Biostatistics, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA

LOTIS-5, AN ONGOING, PHASE 3, RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL

Michal T. Kwiatek, MD, PhD,[1] Carmelo Carlo-Stella, MD,[2] Andrzej Urban, MD, PhD,[3] Andrew Niewiarowski, PhD,[4] Luqiang Wang, PhD,[5] Mehdi Hamadani, MD[6]

[1]Centrum Medyczne Pratia, Poznań, Poland; [2]Department of Biomedical Sciences, Humanitas University, and Department of Oncology and Hematology, Humanitas Research Hospital–IRCCS, Milano, Italy; [3]ADC Therapeutics SA, Épalinges, Switzerland; [4]ADC Therapeutics (UK) Ltd, London, UK; [5]ADC Therapeutics America, Inc., Murray Hill, NJ, USA; [6]Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY WITH A PD-1 KNOCKOUT (CB-010) IN PATIENTS WITH RELAPSED/REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL): UPDATED PHASE 1 RESULTS FROM THE ANTLER TRIAL

B. Hu,[1] L. Nastoupil,[2] H. Holmes,[3] A. Hamdan,[4] A.S. Kanate,[5] U. Farooq,[6] M. Cherry,[7] E. Brem,[8] L Pinter-Brown,[8] D. Ermann,[1] M. Husnain,[9] K. Micklethwaite,[10] S. Rizvi,[11] A. Hammad,[11] B. Thompson,[11] E. Zudaire,[11] S. Portella,[11] M. Hamadani,[12] J. Essell,[13] S. O'Brien[8]

[1]Huntsman Cancer Institute, Salt Lake City, Utah, USA; [2]MD Anderson Cancer Institute, Houston, Texas, USA; [3]Texas Oncology – Baylor Sammons Cancer Center, Dallas, Texas, USA; [4]University of California San Diego Health, San Diego, California, USA; [5]HonorHealth, Scottsdale, Arizona, USA; [6]University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA; [7]Morristown Medical Center, Morristown, New Jersey, USA; [8]University of California Irvine, Irvine, California, USA; [9]University of Arizona Cancer Center, Tucson, Arizona, USA; [10]New South Wales Health, St Leonards, New South Wales, Australia; [11]Caribou Biosciences, Inc., Berkeley, California, USA; [12]Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA; [13]Oncology Hematology Care, Cincinnati, Ohio, USA

INCIDENCE OF CENTRAL NERVOUS SYSTEM RELAPSE IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: IMPLICATIONS FOR CENTRAL NERVOUS SYSTEM PROPHYLAXIS

Izel Okcu,[1] Jihao Zhou,[2] Yucai Wang,[1] Allison M. Bock,[3] Muhamad Alhaj Moustafa,[4] Firas Baidoun,[4] Han W. Tun,[4] Allison C. Rosenthal,[5] Patrick B. Johnston,[1] Brian F. Kabat,1 Lisa M. Rimsza,[5] Thomas M. Habermann,[1] Grzegorz S. Nowakowski[1]

[1]Mayo Clinic, Rochester, MN, USA; [2]Shenzhen People's Hospital, Shenzhen, China; [3]University of Utah, Salt Lake City, Utah, USA; [4]Mayo Clinic, Jacksonville, FL, USA; [5]Mayo Clinic, Phoenix, AZ, USA

e-Posters are available on your phone/tablet via the conference app or on your laptop/desktop via the conference portal.

DOSE ADJUSTMENT OUTCOMES IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

Shayna Sarosiek, MD[1]; Steven P. Treon, MD, PhD[1]; M. Lia Palomba, MD[2]; Meletios-Athanasios Dimopoulos, MD[3]; Jorge J. Castillo, MD[1]; Hillary M. Peltier, PhD[4]; Vincent Girardi, MS[4]; Alex Bokun, PharmD[5]; Anat Raz, MD[4]; Michelle Pacia, PharmD, MBA[4]; Christian Buske, MD[6]

[1]Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; [2]David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, NY, USA; [3]National and Kapodistrian University of Athens School of Medicine, Athens, Greece; [4]AbbVie, North Chicago, IL, USA; [5]Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, NJ, USA; [6]Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany

HIGH INCIDENCE OF CYTOMEGALOVIRUS (CMV) REACTIVATION IN PATIENTS RECEIVING CAR T-CELL THERAPY

Tamer Othman, MD[1]; John Baird, MD[1]; Stacy Pak, PharmD[1]; Yi-Ping Wen, NP[1]; Geoffrey Shouse DO, PhD[1]; Liana Nikolaenko, MD[1]; Matthew Mei, MD1; Stephen J. Forman, MD[1]; Elizabeth Budde, MD, PhD[1]; Sanjeet Singh Dadwal, MD, FACP, FIDSA[2]

[1]Department of Hematology and HCT, City of Hope, Duarte, CA, USA; [2]Infectious Disease, City of Hope, Duarte, CA, USA

PIRTOBRUTINIB IN RELAPSED/REFRACTORY CLL/SLL: RESULTS FROM BTKI NAÏVE COHORT IN THE PHASE 1/2 BRUIN STUDY

Manish Patel[1], Toby A. Eyre[2], Ewa Lech-Maranda[3], Lindsey E. Roeker[4], Noriko Fukuhara[5], Jennifer A. Woyach[6], William G. Wierda[7], Jennifer R. Brown[8], Krish Patel[9], Constantine S. Tam[10], Bita Fahkri[11], Paolo Abada[12], Donald E. Tsai[12], Richard Sizelove[13], Wojciech Jurczak[14]

[1]Florida Cancer Specialists/Sarah Cannon Research Institute, FL, USA; [2]Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; [3]Institute of Hematology and Transfusion Medicine, Warsaw, PL; [4]Memorial Sloan Kettering Cancer Center, NY, USA; [5]Tohoku University Hospital, Sendai, JP; [6]The Ohio State University Comprehensive Cancer Center, OH, USA; [7]UT MD Anderson Cancer Center, TX, USA; [8]Dana-Farber Cancer Institute and Harvard Medical School, MA, USA; [9]Swedish Cancer Institute, WA, USA; [10]Alfred Hospital and Monash University, Melbourne, AUS; [11]Division of Hematology at Stanford University School of Medicine, CA, USA; [12]Loxo@Lilly, Indianapolis, IN, USA; [13]Eli Lilly and Company, Indianapolis, IN, USA; [14]Maria Sklodowska-Curie National Research Institute of Oncology, Krakow PL

ECONOMIC BURDEN OF ADVERSE EVENTS AMONG RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL IN THE TRANSCEND MCL CLINICAL TRIAL

Pallavi Patwardhan, PhD, BSPharm,[1] Ashley Martin, PhD,[2] Sana Mirza, MPH,[2] Abraham D. Lee, MS,[2]* Sean Garrison PhD,[1] Debasmita Roy PhD,[1] Thomas Carattini, PharmD, MBA,[1] November H. McGarvey, PhD, MPH,[2] Tycel J. Phillips, MD[3]

[1]Bristol Myers Squibb, Princeton, NJ, USA; [2]BluePath Solutions, Los Angeles, CA, USA; [3]City of Hope National Medical Center, Duarte, CA, USA

STAGING PATTERNS IN BLOOD AND LYMPH NODES IN PATIENTS WITH LIMITED STAGE CUTANEOUS T-CELL LYMPHOMA (CTCL)

Darina Paulino, Jeffrey Switchenko, Mary Jo Lechowicz, Pamela Allen, Brittany Adams, Shel Speegle, Katherine Case, Katelin Baird

Winship Cancer Institute of Emory University, Atlanta GA USA

NEMTABRUTINIB PLUS VENETOCLAX VERSUS VENETOCLAX PLUS RITUXIMAB IN TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: PHASE 3 BELLWAVE-010 STUDY

David Lavie[1]; Muhit Ozcan[2]; Arvind Chaudhry[3]; Xuan Zhou[4]; Ima Paydar[4]; Mohammed Z. H. Farooqui[4]; Paolo Ghia[5]

[1]Hadassah Medical Center, Jerusalem, Israel; [2]Ankara University School of Medicine, Ankara, Türkiye; [3]Summit Cancer Centers, Spokane Valley, WA, USA; [4]Merck & Co., Inc., Rahway, NJ, USA; [5]Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

TREATMENT OF ANTI-MYELIN-ASSOCIATED-GLYCOPROTEIN (MAG) ANTIBODY NEUROPATHY WITH ZANUBRUTINIB IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CLINICAL VIGNETTE

Romy Pein, BA,[1] Amir Steinberg, MD[2]

[1]New York Medical College, Valhalla, NY, USA; [2]Department of Hematology and Oncology, Westchester Medical Center, Valhalla, NY, USA

AN ECONOMIC MODEL TO ESTIMATE COSTS OF SELECT ADVERSE EVENTS AMONG PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES FOR R/R MCL

TJ Phillips,[1] J Badaracco,[2] W Ngantung,[2] T Carattini,[3] P Patwardhan[3]

[1]City of Hope National Medical Center, Duarte, CA, USA; [2]BluePath Solutions, Los Angeles, CA, USA; [3]Bristol Myers Squibb, Princeton, NJ, USA

COFORMULATED FAVEZELIMAB AND PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH ANTI–PD-1 REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A PHASE 3 KEYFORM-008 STUDY

David Lavie[1]; John Timmerman[2]; Ramón García-Sanz[3]; Won Seog Kim[4]; Tae Min Kim[5]; Abraham Avigdor[6]; Daan Dierickx[7]; Deepa Jagadeesh[8]; Daniel Molin[9]; Muhit Ozcan[10]; Omur Gokmen Sevindik[11]; Hayder Saeed[12]; Yulia Sidi[13]; Pallavi Pillai[13]; Patricia Marinello[13]; Alex F. Herrera[14]

[1]Hadassah Medical Center, Jerusalem, Israel; [2]UCLA Medical Center, Los Angeles, CA, USA; [3]University Hospital of Salamanca, Salamanca, Spain; [4]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; [5]Seoul National University Hospital, Seoul, Republic of Korea; [6]Sheba Medical Center, Ramat Gan, and School of Medicine, Tel Aviv University, Tel Aviv, Israel; [7]University Hospitals Leuven, Leuven, Belgium; [8]Cleveland Clinic, Cleveland, OH, USA; [9]Uppsala University, Uppsala, Sweden; [10]Ankara University School of Medicine, Ankara, Türkiye; [11]Istanbul Medipol University, International School of Medicine, Istanbul, Türkiye; [12]Moffitt Cancer Center, Tampa, FL, USA; [13]Merck & Co., Inc., Rahway, NJ, USA; [14]City of Hope, Duarte, CA, USA

HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND SYMPTOMS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH ODRONEXTAMAB MONOTHERAPY IN THE PHASE 2 ELM-2 STUDY

H. Miles Prince,[1] Elżbieta Iskierka-Jażdżewska,[2] Won Seog Kim,[3] Seok-Goo Cho,[4] Tae Min Kim,[5] Isidro Jarque,[6] Tadeusz Robak,[2] Michelle Poon,[7] Sung Yong Oh,[8] Francesca Lim,[9] Cecilia Carpio,[10] Tran-Der Tan,[11] Sabarish Ayyappan,[12] Antonio Gutierrez,[13] Huilai Zhang,[14] Junning Cao,[15] Mingzhi Zhang,[16] Benoît Tessoulin,[17] Jingjin Li,[18] Cristina Ivanescu,[19] Matthew Reaney,[20] Aafia Chaudhry,[18] Hesham Mohamed,[18] Srikanth Ambati,[18] James Harnett,[18] Lei Chi,[18] Jan Walewski,[21] on behalf of ELM-2 Investigators

[1]Epworth Healthcare and University of Melbourne, Australia; [2]Copernicus Memorial Hospital, Poland; [3]Samsung Medical Center, Sunyunkwan University School of Medicine, Republic of Korea; [4]Seoul St. Mary's Hospital, Republic of Korea; [5]Seoul National University Hospital, The Catholic University of Korea, Republic of Korea; [6]Hospital Universitario La Fe, Spain; [7]National University Cancer Institute, Singapore; [8]Dong-A University Hospital, Republic of Korea; [9]Singapore General Hospital, Singapore; [10]Vall D'Hebron Hospital, Spain; [11]Koo Foundation Sun Yat Sen Cancer Center, Taiwan; [12]University of Iowa Hospital, USA; [13]Hospital Universitari Son Espases, IdISBa Palma, Spain; [14]Tianjin Medical University Cancer Institute, China; [15]Fudan University Shanghai Cancer Center, China; [16]The First Affiliated Hospital of Zhengzhou University, China; [17]Nantes University Hospital, France; [18]Regeneron Pharmaceuticals, Inc., USA; [19]IQVIA, Netherlands; [20]IQVIA Inc., UK; [21]Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Poland

SAFETY AND TOLERABILITY OF E7777 (IMPROVED PURITY DENILEUKIN DIFTITOX [ONTAK]) IN PATIENTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA: RESULTS FROM PIVOTAL STUDY 302

Christiane Querfeld[1], MD, PhD; Miles Prince[2], MD, FRCPA, Larisa J Geskin[3], MD, Oleg E Akilov[4], MD, PhD, Timothy M. Kuzel[5], MD, FACP, Chean Eng Ooi[6], PhD, Dongyuan Xing[6], PhD, Nicholas Sauter6, MD, Preeti Singh[7], MD, Myron Czuczman[7], MD, Francine Foss[8], MD

[1]Department of Dermatology, City of Hope Comprehensive Cancer Center, Duarte, CA; [2]Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; [3]Department of Dermatology, Columbia University Medical Center, NY; [4]Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA; [5]Department of Medicine, Rush University Medical Center, Chicago, IL; [6]Eisai Inc., Nutley, NJ; [7]Citius Pharmaceuticals, Cranford, NJ; [8]Yale Cancer Center, Yale Medical Group, New Haven, CT

HEALTH AND ECONOMIC IMPACT OF CAR T VEIN-TO-VEIN TIME IN RELAPSED/REFRACTORY 2L LBCL PATIENTS: A US COST-EFFECTIVENESS ANALYSIS

Olalekan O. Oluwole, MD[1], Markqayne Ray, PharmD[2], Hanxiao Ma, MHS[3], Harry Smith, MSc[2], Rishika Sharma, MEng[3], Anik R Patel, PhD[2], Nate Smith, PhD[3]

[1]Vanderbilt University School of Medicine, Nashville, TN; [2]Kite, A Gilead Company, Santa Monica, CA; [3]Maple Health Group, LLC, New York, New York

EFFICACY AND SAFETY OF ZILOVERTAMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 2 WAVELINE-004 STUDY

Muhit Ozcan[1]; Fangfang Lv[2]; Lalita Norasetthada[3]; Ewa Paszkiewicz-Kozik[4]; Joaquín Díaz-Schmidt[5]; Dipenkumar Modi[6]; Alexander Fossa[7]; Sagun Goyal[8]; Won Seog Kim[9]; Seung Tae Lee[10]; Armando Santoro[11]; Mehmet Sonmez[12]; Kumudu Pathiraja[13]; Nishitha Reddy[13]; Patricia Marinello[13]; Yuqin Song[14]

[1]Ankara University School of Medicine, Ankara, Türkiye; [2]Fudan University Shanghai Cancer Center, Shanghai, China; [3]Chiang Mai University, Chiang Mai, Thailand; [4]Maria Sklodowska–Curie National Research Institute of Oncology, Warsaw, Poland; [5]Clínica Alemana, Santiago, Chile; [6]Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA; [7]Oslo Universitetssykehus, Radiumhospitalet, Oslo, Norway; [8]Saint Louis University Cancer Center, St. Louis, MO, USA; [9]Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; [10]University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; [11]Humanitas University, Pieve Emanuele and IRCCS Humanitas Research Hospital- Humanitas Cancer Center Rozzano, Milan, Italy; [12]Karadeniz Teknik Universitesi Tip Fakultesi-Hematoloji, Trabzon, Turkiye; [13]Merck & Co., Inc., Rahway, NJ, USA; [14]Peking University Cancer Hospital and Institute, Beijing, China

MANAGEMENT OF RELAPSED CLASSICAL HODGKIN LYMPHOMA (CHL) IN PREGNANCY

Jacqueline Rios[1], Meera Khosla[1], Hala Hassanain[1], Ethan A. Burns[1,2], Chih-Hang Anthony Tang[2,3], Chih-Chi Andrew Hu[2,3], Hanh Mai[2], Carrie Yuen[2], Shilpan Shah[2], Siddhartha Ganguly[2], Sai Ravi Pingali[2,3]

[1]Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA; [2]Department of Academic Medicine, Houston Methodist Hospital, Houston, TX, USA; [3]Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA

PIRTOBRUTINIB IN POST-CBTKI CLL/SLL: ~30 MONTHS FOLLOW-UP AND SUBGROUP ANALYSIS WITH/WITHOUT PRIOR BCL2I FROM THE PHASE 1/2 BRUIN STUDY

Lindsey Roeker[1], Jennifer Woyach[2] Jennifer Brown[3], Paolo Ghia[4], Krish Patel[5], Toby Eyre[6], Talha Munir[7], Ewa Lech-Maranda[8], Nicole Lamanna[9], Constantine S. Tam[10], John Seymour[11], Benoit Tessoulin[12], Nirav Shah[13], Chaitra Ujjani[14], Bita Fahkri[15], Catherine Coombs[16], Ian Flinn[17], Manish Patel[18], Sunita Nasta[19], Jonathon Cohen[20], Alvaro Alencar[21], Chan Cheah[22], Shuo Ma[23], Joanna Rhoades[24], Deepa Jagadeesh[25], Pier Luigi Zinzani[26], Anders Osterborg[27], Koji Izutsu[28], Donald Tsai[29], Paolo Abada[29], Minna Balbas[29], Jian Li[29], Amy Ruppert[30], Wojciech Jurczak[31], William Wierda[32]

[1]Memorial Sloan Kettering Cancer Center NY, USA; [2]The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; [3]Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; [4]Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy; [5]Swedish Cancer Institute, Seattle, WA, USA; [6]Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, UK; [7]Department of Haematology, St. James's University Hospital, Leeds, UK; [8]Institute of Hematology and Transfusion Medicine, Poland; [9]Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; [10]Alfred Health and Monash University, Melbourne, Victoria, Australia; [11]Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia; [12]Haematology Department, University Hospital, Nantes, France; [13]Medical College of Wisconsin, Milwaukee, WI, USA; [14]Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [15]Division of Hematology at Stanford University School of Medicine, Stanford, CA, USA; [16]University of California Irvine, Irvine, CA, USA; [17]Sarah Cannon Research Institute, Nashville, TN, USA; [18]Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA; [19]Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; [20]Winship Cancer Institute, Emory University, Atlanta, GA, USA; [21]Sylvester Comprehensive Cancer, Miami, FL, USA; [22]Linear Clinical Research and Sir Charles Gairdner Hospital, West Australia, AUS; [23]Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; [24]Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; [25]Cleveland Clinic, Cleveland, OH, USA; [26]Institute of Hematology "Seràgnoli" University of Bologna, Italy; [27]Karolinska Institute and Karolinska University Hospital, Stockholm, SE; [28]National Cancer Center Hospital, Tokyo, JP; [29]Loxo@ Lilly, Indianapolis, IN, USA; [30]Eli Lilly and Company, Indianapolis, IN, USA; [31]Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; [32]MD Anderson Cancer Center, Houston, TX, USA

e-Posters are available on your phone/tablet via the conference app or on your laptop/desktop via the conference portal.

QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL PREDICTS COMBINATION ACTIVITY OF CD19-TARGETED LONCASTUXIMAB TESIRINE CO-DOSED WITH A CD20/CD3 T-CELL BISPECIFIC (EPCORITAMAB) IN DIFFUSE LARGE B-CELL LYMPHOMA

Yuezhe Li[1], A. Katharina Wilkins[1], Jimena Davis[1], Tim Knab[1], Karen Russo[2], Joseph P. Boni[2]

[1]Metrum Research Group, Tariffville, CT, USA; [2]ADC Therapeutics America, Murray Hill, NJ, USA

REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B- CELL LYMPHOMA IN THE UNITED STATES BY PRIMARY REFRACTORY STATUS

Kim Saverno,[1] Kristin M. Zimmerman Savill,[2] Bruce Feinberg,[2] John Galvin,[1] Prathamesh Pathak,[2] Theresa Amoloja,[1] Narendranath Epperla,[3] Loretta J. Nastoupil[4]

[1]Incyte Corporation, Wilmington, DE, USA; [2]Cardinal Health, Dublin, OH, USA; [3]The Ohio State University, Columbus, OH, USA; [4]The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R-CHOP VERSUS R-CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE DLBCL-2

Laurie H. Sehn[1], Martine Chamuleau[2], Georg Lenz[3], Michael Clausen[4], Corinne Haioun[5], Koji Izutsu[6], Andrew Davies[7], Jun Zhu[8], Toshiko Oki[9], Edith Szafer-Glusman[9], Rebekah Conlon[9], Hueiyu Chiou[9], David Ipe[9], Brian Elliott[10], Jun Wu[9], Gilles Salles[11]

[1]BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada; [2]Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; [3]Department of Medicine A for Hematology, Oncology and Pneumology, Universitätsklinikum Münster, Münster, Germany; [4]Sygehus Lillebælt, Vejle, Denmark; [5]Hopital Henri Mondor, Créteil, France; [6]National Cancer Center Hospital, Tokyo, Japan; [7]Southampton NIHR/Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom; [8]Beijing Cancer Hospital, Beijing, China; [9]AbbVie, North Chicago, IL, USA; [10]Genmab, Plainsboro, NJ, USA; [11]Memorial Sloan Kettering Cancer Center, New York, NY, USA

REAL-WORLD COMPARATIVE EFFECTIVENESS OF COVALENT BRUTON TYROSINE KINASE INHIBITORS (CBTKI) AMONG PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)

Tycel Phillips[1], Taavy A. Miller[2], Jingru Wang[2], Mark A. Guinter[2], Amy Pierre[2], Gregory A. Maglinte[3], Erlene K. Seymour[3]

[1]City of Hope, Duarte, California, United States of America; [2]Flatiron, New York, United States of America; [3]BeiGene USA, Inc., San Mateo, CA, United States of America

EPCORE FL-1: PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB WITH RITUXIMAB AND LENALIDOMIDE (R2) VS R2 ALONE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Lorenzo Falchi, MD,[1] Franck Morschhauser, MD, PhD,[2] Kim Linton, MD, PhD,[3] Huiqiang Huang, MD, PhD,[4] Faith Galderisi, DO,[5] Syed Quadri, PharmD,[5] Lingmin Zeng, PhD,[5] Daniela Hoehn,[6] John F. Seymour, MBBS, PhD[7]

[1]Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY; [2]Hôpital Claude Huriez, Lille, France; [3]Division of Cancer Sciences, University of Manchester, United Kingdom; [4]Sun Yat-sen University, Guangzhou, China; [5]AbbVie, North Chicago, IL; [6]Genmab, Princeton, NJ; [7]Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, Australia

REAL-WORLD OUTCOMES FOLLOWING ADVERSE EVENTS AND DOSE REDUCTION OF FIRST- LINE IBRUTINIB IN MEDICARE BENEFICIARIES WITH CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

Mazyar Shadman, MD[1]; Bhavini P. Srivastava, MSc[2]; Monika Salkar, PhD[2]; Chadi Saifan, MD[2]; Barnabie, C. Agatep, MPH[3]; Barton Jones, MS[3]; Olga Ryan, DrPH, MPH, MBA[2]; Shaffee Bacchus, PharmD[2]; Deborah M. Stephens, DO[4]

[1]Fred Hutchinson Cancer Center, Seattle, WA, USA; [2]AbbVie, North Chicago, IL, USA; [3]Inovalon, Bowie, MD, USA; [4]University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

ACCESS TO CAR T-CELL THERAPY IN THE US AND ITS POTENTIAL IMPACTS ON HEALTH INEQUITIES

A. Chung[1], J. Shafrin[1], S. Vadgama[2], K. Hurley[2], G.L. Shah[3], L.C. Alsfeld[4], S Muthukrishnan[1], M. Perales[3], R.T. Maziarz[5]

[1]FTI Consulting; [2]Kite; [3]Memorial Sloan Kettering Cancer Center; [4]Ochsner Health; [5]Oregon Health & Science University

LATEST RESULTS FROM AN ONGOING FIRST-IN-HUMAN PHASE 1A/B STUDY OF NX-5948, A SELECTIVE BRUTON'S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/ REFRACTORY CLL AND OTHER B-CELL MALIGNANCIES

[1]Nirav N. Shah, [2]Kim Linton, [3]Graham P. Collins, [4]Francesco Forconi, [5]Karan Dixit, [6]Talha Munir, [7]Zulfa Omer, [8]Dima El-Sharkawi, [9]Jeanette Doorduijn, [10]Alvaro Alencar, [11]Pam McKay, [12]John Riches, [13]Mary Gleeson, [14]David Lewis, [15]Allison Winter, [16]Sarah Injac, [16]Ted Shih, [16]Srinand Nandakumar, [16]May Tan, [16]Ganesh Cherala, [16]Erin Meredith, [17]Alexey Danilov

[1]Medical College of Wisconsin, Milwaukee, WI, USA; [2]The Christie Hospital and Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, UK; [3]Oxford University Hospitals NHS Foundation Trust, Oxford, UK; [4]University Hospital Southampton NHS Trust, Southampton, UK; [5]Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; [6]St. James's Hospital, Leeds, UK; [7]University of Cincinnati, Cincinnati, OH, USA; [8]Royal Marsden NHS Foundation Trust, Sutton, UK; [9]Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology; on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC; [10]Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; [11]Beatson West of Scotland Cancer Centre, Glasgow, Scotland; [12]Barts Cancer Institute, Queen Mary University of London, UK; [13]Sarah Cannon Research Institute, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK; [14]Derriford Hospital, Plymouth, UK; [15]Taussig Cancer Institute, Cleveland Clinic Main Campus, Cleveland, OH, USA; [16]Nurix Therapeutics, Inc., San Francisco, CA, USA; [17]City of Hope National Medical Center, Duarte, CA, USA

INTEGRATIVE FUNCTIONAL GENOMICS AND SPATIAL TUMOR MICROENVIRONMENT ANALYSIS OF MANTLE CELL LYMPHOMA REVEAL PROGNOSTIC BIOLOGICAL SUBTYPES

Sunandini Sharma[1], Alyssa Bouska[1], Roshia Ali[1], Simeon Mahov[2,3], WeiWei Zhang[1], Meghana Kesireddy[1], Dylan Jochum[1], Waseem Lone[1], Alicia Gamboa[2,3], Vaishnavi Devarkonda[2,3], Adnan Mansoor[4], Douglas Stewart[5], Lynette Smith[1], Heather Nutsch[1], Jayson Henrickson[1], Salma Elhag[1], Melissa Holzapfel[1], Dario Ghersi[6], Dalia ElGamal[1], Ryan Morrin[7], Prasath Pararajalingam[7], Kai Fu[8], Timothy Greiner[1], Julie M Vose[1], Akil Merchant[2], Bi Chengfeng[1], Javeed Iqbal[1]

[1]Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States; [2]Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, United States; [3]Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; [4]Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; [5]Departments of Oncology and Medicine, University of Calgary, Calgary, Canada; [6]University of Nebraska at Omaha, NE, United States; [7]Simon Fraser University, British Columbia Cancer Agency, Vancouver, Canada; [8]Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

E-Posters

THE EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS STANDARD OF CARE (SCHOLAR-5) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES: AN INDIRECT TREATMENT COMPARISON

Anna Sureda,[1] Swetha Kambhampati,[2] Kim Linton,[3] Karen Cumings,[4] Viktor Chirikov,[4] Alex Mutebi,[5] Anindit Chhibber,[5] Fernando Rivas Navarro,[6] Anthony Wang,[7] Zhijie Ding,[4] Abualbishr Alshreef,[7] Elena Favaro,[6] Daniela Hoehn,[5] Alexey Danilov[2]

[1]Clinical Hematology Department, Institut Català d'Oncologia – L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; [2]City of Hope, Duarte, CA, USA; [3]The Christie NHS Foundation Trust, Manchester Cancer Research Center, and Division of Cancer Sciences, University of Manchester, Manchester, UK; [4]OPEN Health, Hingham, MA, USA; [5]Genmab US Inc., Plainsboro, NJ, USA; [6]Genmab, Copenhagen, Denmark; [7]AbbVie, Inc., North Chicago, IL, USA

QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF LONCASTUXIMAB TESIRINE COMBINED WITH MOSUNETUZUMAB AND GLOFITAMAB HELPS GUIDE DOSING FOR PATIENTS WITH DLBCL

Yuezhe Li,[1] A. Katharina Wilkins,[1] Tim Knab,[1] Amber Svardal,[2] Joseph P. Boni[2]

[1]Metrum Research Group, Tariffville, CT, USA; [2]ADC Therapeutics America, Murray Hill, NJ, USA

FINAL ANALYSIS OF THE RESONATE-2 STUDY: UP TO 10 YEARS OF FOLLOW-UP OF FIRST-LINE IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Jan Burger,[1] Paul Barr,[2] Tadeusz Robak,[3] Carolyn Owen,[4] Alessandra Tedeschi,[5] Anita Sarma,[6] Piers, E.M. Patten,[7] Sebastian Grosicki,[8] Helen McCarthy,[9] Fritz Offner,[10] Edith Szafer-Glusman,[11] Cathy Zhou,[11] Anita Szoke,[11] Lynne Neumayr,[11] James P. Dean,[11] Paolo Ghia,[12] Thomas J. Kipps[13]

[1]Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; [2]Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; [3]Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; [4]Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; [5]Niguarda Ca' Granda Hospital, Milan, Italy; [6]St. James's University Hospital, Leeds, United Kingdom; [7]King's College Hospital, London, United Kingdom; [8]Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesian, Katowice, Poland; [9]Royal Bournemouth General Hospital, Bournemouth, United Kingdom; [10]Universitair Ziekenhuis Gent, Gent, Belgium; [11]AbbVie, North Chicago, IL, USA; [12]Medical School, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; [13]University of California San Diego Moores Cancer Center, La Jolla, CA, USA

EXTENDED FOLLOW-UP BEYOND 2.5 YEARS SHOWS LONG-TERM EFFICACY IN COMPLETE RESPONDERS FOLLOWING EPCORITAMAB MONOTHERAPY IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

C. Thieblemont,[1] Y.H. Karimi,[2] H. Ghesquieres,[3] C.Y. Cheah,[4] M.R. Clausen,[5] D. Cunningham,[6] W. Jurczak,[7] T. Feldman,[8] K.M. Linton,[9] J.M. Vose,[10] U. Farooq,[11] W.S. Kim,[12] M.H. Dinh,[13] Y. Liu,[14] Y. Wang,[14] S. Kanoun,[15] N. Kilavuz,[14] M. Sacchi,[14] P.J. Lugtenburg,[16] M. Hutchings[17]

[1]Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France; [2]University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; [3]Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; [4]Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia; [5]Vejle Hospital, Vejle, Denmark; [6]The Royal Marsden NHS Foundation Trust, Sutton, UK; [7]MSC National Research Institute of Oncology, Kraków, Poland; [8]John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA; [9]The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK; [10]University of Nebraska Medical Center, Omaha, NE, USA; [11]University of Iowa, Iowa City, IA, USA; [12]Samsung Medical Center, Seoul, Republic of Korea; [13]AbbVie, North Chicago, IL, USA; [14]Genmab, Plainsboro, NJ, USA; [15]Cancer Research Center of Toulouse, Toulouse, France; [16]On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands; [17]Rigshospitalet and University of Copenhagen, Copenhagen, Denmark

PHASE 1B OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (LOTIS-7)

Emily C. Ayers, MD,[1] Julien Depaus, MD,[2] Fritz Offner, MD, PhD,[3] Marie Hu, MD,[4] Craig Okada, MD,[5] Andrzej Urban, MD, PhD,[6] Andrew Niewiarowski, PhD,[7] Juan Pablo Alderuccio, MD[8]

[1]Division of Hematology & Oncology, University of Virginia, Charlottesville, VA, USA; [2]Centre Hospitalier Universitaire, Université Catholique de Louvain Namur – Site Godinne, Yvoir, Belgium; [3]Department of Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium; [4]Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA; [5]Oregon Health & Science University, Portland, OR, USA; [6]ADC Therapeutics SA, Épalinges, Switzerland; [7]ADC Therapeutics (UK) Ltd, London, UK; [8]Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA

MAINTENANCE OF MODERATE TO HIGH LEVELS OF FUNCTIONING AND QUALITY OF LIFE (QOL) WITH ODRONEXTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Jose C. Villasboas,[1] Benoît Tessoulin,[2] Seok-Goo Cho,[3] Michal Taszner,[4] Tae Min Kim,[5] Silvana Novelli,[6] Michele Merli,[7] Ana Jiménez Ubieto,[8] Michelle Poon,[9] David Tucker,[10] Jan Walewski,[11] Shuhua Yi,[12,13] Yuqin Song,[14] Geoffrey Chong,[15] Emmanuel Bachy,[16] Stephanie Guidez,[17] Aranzazu Alonso,[18] Deepa Jagadeesh,[19] Wei Zhang,[20] Laura Magnano Mayer,[21] Elżbieta Iskierka-Jażdżewska,[22] Monica Tani,[23] Jingxian Cai,[24] Cristina Ivanescu,[25] Matthew Reaney,[26] Aafia Chaudhry,[24] Hesham Mohamed,[24] Srikanth Ambati,[24] James Harnett,[24] Lei Chi,[24] Stefano Luminari,[27] on behalf of ELM-2 Investigators

[1]Mayo Clinic, USA; [2]Nantes University Hospital, France; [3]Seoul St. Mary's Hospital, Republic of Korea; [4]Medical University of Gdańsk, Poland; [5]Seoul National University Hospital, Republic of Korea; [6]Hospital de la Santa Creu i Sant Pau, Spain; [7]Ospedale di Circolo e Fondazione Macchi, Italy; [8]Hospital Universitario 12 de Octubre, Spain; [9]National University Cancer Institute, Singapore; [10]Royal Cornwall Hospital, UK; [11]Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Poland; [12]National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, China; [13]Tianjin Institutes of Health Science, China; [14]Peking University Cancer Hospital and Institute, China; [15]Olivia Newton-John Cancer Centre, Australia; [16]Hospices Civils de Lyon and Université Claude Bernard Lyon 1, France; [17]Centre Hospitalier Universitaire, France; [18]Hospital Universitario Quiron Salud Madrid, Spain; [19]Cleveland Clinic, USA; [20]Peking Union Medical College Hospital, China; [21]Hospital Clínic de Barcelona, Spain; [22]Copernicus Memorial Hospital, Poland; [23]Santa Maria delle Croci Hospital, Italy; [24]Regeneron Pharmaceuticals, Inc., USA; [25]IQVIA, Netherlands; [26]IQVIA Inc., UK; [27]Azienda Unità Sanitaria Locale-IRCCS, Italy

EPCORITAMAB INDUCES DEEP RESPONSES IN RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): SAFETY AND POOLED EFFICACY DATA FROM EPCORE NHL-1 PIVOTAL AND CYCLE (C) 1 OPTIMIZATION (OPT) FL COHORTS

U. Vitolo,[1] P.J. Lugtenburg,[2] M.E.D. Chamuleau,[3] J.M. Sancho,[4] K.M. Linton,[5] K. Sonnevi,[6] D.J. Lewis,[7] M.A. Canales,[8] J.M. Vose,[9] J.C. Chavez,[10] H. Ghesquieres,11 C. Thieblemont,[12] M. Hutchings,[13] A. Sureda,[14] T. Cochrane,[15] M.R. Clausen,[16] S. Leppä,[17] E. Gyan,[18] E. Favaro,[19] D. Hoehn,[20] I. Altıntaş,[21] C. Morehouse,[20] Z. Li,[20] R. Conlon,[22] W. Jurczak[23]

[1]Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy; [2]On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands; [3]On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands; [4]Catalan Institute of Oncology (ICO), ICO Hospital Germans Trias i Pujol, Badalona, Spain; [5]The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK; [6]Karolinska Institutet, Stockholm, Sweden; [7]University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK; [8]Clínica Universidad de Navarra, Pamplona, Spain; [9]University of Nebraska Medical Center, Omaha, NE, USA; [10]Moffitt Cancer Center, Tampa, FL, USA; [11]Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; [12]Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France; [13]Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; [14]Clinical Hematology Department, Institut Català d'Oncologia – L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; [15]Gold Coast University Hospital, Southport, Queensland, Australia; [16]Vejle Hospital, Vejle, Denmark; [17]University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; [18]Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Tours, CIC INSERM U1415, Tours, France; [19]Genmab, Copenhagen, Denmark; [20]Genmab, Plainsboro, NJ, USA; [21]Genmab, Utrecht, Netherlands; [22]AbbVie, North Chicago, IL, USA; [23]MSC National Research Institute of Oncology, Kraków, Poland

TRIAL IN PROGRESS: PHASE 3 STUDY OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND MARGINAL ZONE LYMPHOMA (MZL) (OLYMPIA-5)

Umberto Vitolo,[1] Michele Merli,[2] Lalita Norasetthada,[3] Timothy Wassenaar,[4] Eva Maria Donato Martín,[5] Sabela Bobillo,[6] Biyi Shen,[6] Dina M. Flink,[6] Min Zhu,[6] Soujanya Chandrasekharan,[6] Jurriaan Brouwer-Visser,[6] Aafia Chaudhry,[6] Hesham Mohamed,[6] Srikanth Ambati,[6] Raúl Córdoba[7]

[1]Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy; [2]Ospedale di Circolo e Fondazione Macchi, Varese, Italy; [3]Chiang Mai University, Chiang Mai, Thailand; [4]ProHealth Care, Waukesha, WI, USA; [5]Hospital Universitario Doctor Peset, Valencia, Spain; [6]Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; [7]Fundación Jiménez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

PIRTOBRUTINIB IN PRIOR CBTKI R/R MCL: PHASE 1/2 BRUIN STUDY UPDATES INCLUDING HIGH-RISK SUBGROUP ANALYSES

Yucai Wang[1], Jonathon B. Cohen[2], Nirav N. Shah[3], Wojciech Jurczak[4], Pier Luigi Zinzani[5], Chan Y. Cheah[6], Toby A. Eyre[7], Chaitra S. Ujjani[8], Youngil Koh[9], Won Seog Kim[10], Sunita D. Nasta[11], Ian Flinn[12], Benoit Tessoulin[13], Shuo Ma[14], Alvaro J. Alencar[15], David J. Lewis[16], Jennifer A. Woyach[17], Kami J Maddocks[17], Krish Patel[18], Joanna Rhodes[19], Constantine S. Tam[20], John F. Seymour[21], Hirokazu Nagai[22], Julie M. Vose[23], Bita Fakhri[24], Marc S. Hoffmann[25], Francisco Hernandez-Ilizaliturri[26], Andrew D. Zelenetz[27], Anita Kumar[27], Talha Munir[28], Donald Tsai[29], Minna Balbas[29], Bin Liu[29], Amy S. Ruppert[30], Bastien Nguyen[29], Lindsey E. Roeker[27], Michael L. Wang[31]

[1]Division of Hematology, Mayo Clinic, Rochester, MN, USA; [2]Winship Cancer Institute, Emory University, Atlanta, GA, USA; [3]Medical College of Wisconsin, Milwaukee, WI, USA; [4]Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; [5]Institute of Hematology "Seràgnoli" University of Bologna, Italy; [6]Linear Clinical Research and Sir Charles Gairdner Hospital, Western Australia, Australia; [7]Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; [8]Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [9]Department of Internal Medicine, Seoul National University Hospital, Korea; [10]Hematology and Oncology at Sungkyunkwan University School of Medicine, Seoul, Korea; [11]Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA; [12]Sarah Cannon Research Institute, Nashville, TN, USA; [13]Haematology Department, University Hospital, Nantes, France; [14]Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; [15]Sylvester Comprehensive Cancer Center, Miami, Fl, USA; [16]University Hospitals Plymouth NHS, UK; [17]The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; [18]Swedish Cancer Institute, Seattle, WA, USA; [19]Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; [20]Alfred Health and Monash University, Melbourne, Victoria, Australia; [21]Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia; [22]Department of Hematology and Oncology Research, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan; [23]University of Nebraska Medical Center, Omaha, NE, USA; [24]Division of Hematology at Stanford University School of Medicine, Stanford, CA, USA; [25]The University of Kansas Cancer Center, KS, USA; [26]Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; [27]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [28]Department of Haematology, St. James's University Hospital, Leeds, UK; [29]Loxo@Lilly, Indianapolis, USA; [30]Eli Lilly and Company, Indianapolis, IN, USA; [31]MD Anderson Cancer Center, Houston, TX, USA

PRIMARY THYROID DIFFUSE LARGE B CELL LYMPHOMA MASKING AS LYMPHOCYTIC THYROIDITIS IN A PATIENT WITH HASHIMOTO'S THYROIDITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS

Chalothorn Wannaphut MD[1], Ryon Nakasone MD[2], Jodi Kagihara MD[2]

[1]Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA; [2]Division of Medical Oncology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA

ALPHA3: A PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF FIRST-LINE (1L) CONSOLIDATION WITH CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) AND MINIMAL RESIDUAL DISEASE (MRD) AFTER RESPONSE TO STANDARD THERAPY

Jason Westin, MD[1]; John M. Burke, MD[2]; Houston E. Holmes, MD[3]; Edward J. Licitra, MD, PhD[4]; Rushang D. Patel, MD, PhD[5]; Amy Feng, PhD[6]; Lynn Navale, MS[6]; Srinivas Ghatta, PhD[6]; John B. Le Gall, MD[6]; Alex F. Herrera, MD[7] on behalf of the ALPHA3 investigators

[1]University of Texas MD Anderson Cancer Center, Houston, TX, USA; [2]US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA; [3]Texas Oncology, Dallas, TX, USA; [4]Astera Cancer Center, East Brunswick, NJ, USA; [5]AdventHealth Cancer Institute, Orlando, FL, USA; [6]Allogene Therapeutics, San Franscisco, CA, USA; [7]City of Hope National Medical Center, Duarte, CA, USA

CALQUENCE®

acalabrutinib 100 mg tablets

EXPLORE LONG-TERM DATA

EFFICACY AND SAFETY RESULTS WITH UP TO 6 YEARS OF MEDIAN FOLLOW-UP*[1]

Learn more at calquencehcp.com or scan here

*At median 74.5-month follow-up (range: 0.0-89.0 months).[1]

Reference: 1. Sharman JP, et al. Abstract presented at: ASH annual meeting; December 9-12, 2023; San Diego, CA. Abs 636.

AstraZeneca

SAVE THE DATE

University of Nebraska Medical Center℠
Nebraska Medicine

2026 PAN PACIFIC LYMPHOMA CONFERENCE

July 20-24 • Fairmont Orchid, Hawaii

CALL FOR ABSTRACTS

Deadline: Friday, March 27, 2026

www.unmc.edu/panpacificlymphoma